# 2026年2月28日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 腺泡化生细胞产生半同质性生态位并与免疫细胞相互作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41758082)
**期刊：** Gastroenterology
**PMID：** 41758082
**DOI：** 10.1053/j.gastro.2025.12.014

### 第一部分 原文与翻译

**英文原标题：** Acinar Metaplastic Cells Generate Semi-Homogeneous Niches and Interact With Immune Cells.

> **英文摘要：**
> BACKGROUND & AIMS: Metaplasia is the first stage in cell transformation that can lead to malignancy. Acinar metaplastic cells form premalignant lesions that have the potential to become invasive and develop into a deadly pancreatic ductal adenocarcinoma. We and others previously showed that acinar metaplastic cells are heterogeneous and include 7 distinct subtypes. The distribution of metaplastic cell types across lesions, their interactions with one another, and their crosstalk with stromal and immune cells remain largely unknown. METHODS: We performed single-cell RNA sequencing, spatial transcriptomics, and hematoxylin-eosin staining of mouse and human samples. RESULTS: We found a nonrandom distribution of metaplastic cells along the lesions, with cells of the same type tending to be close to each other, suggesting proliferation after defining cell identity. We also observed that metaplastic proliferating cells and senescent cells, as well as metaplastic tuft-like cells and metaplastic chief-like cells, frequently colocalize within the same lesions. We investigated the metaplastic cell types associated with higher-grade lesions and found increased expression of Muc4, Lcn2, and Cd274, highlighting genes that may drive the malignant process. In addition, we discovered niches that are highly enriched for specific metaplastic cell types and identified immune cells within these regions. We detected close interactions between metaplastic uncommitted cells and immunosuppressive neutrophils, as well as between metaplastic senescent cells and a subpopulation of macrophages. CONCLUSIONS: Our findings suggest that metaplastic cells can program immune cells in a specific manner at an early stage of cancer initiation to support an immunosuppressive microenvironment within defined niches.

> **中文摘要：**
> 背景与目的：化生是细胞转化的第一阶段，可导致恶性肿瘤。腺泡化生细胞形成癌前病变，具有演变为侵袭性并发展为致死性胰腺导管腺癌的潜力。我们及其他研究者此前已证明，腺泡化生细胞具有异质性，包含 7 个不同的亚型。化生细胞亚型在病变中的分布、它们之间的相互作用，以及它们与间质细胞和免疫细胞的交叉对话在很大程度上仍是未知的。方法：我们对小鼠和人类样本进行了单细胞 RNA 测序、空间转录组学和苏木精-伊红染色。结果：我们发现化生细胞在病变中呈现非随机分布，同类型的细胞倾向于彼此靠近，这表明在确定细胞身份后发生了增殖。我们还观察到，化生增殖细胞与化生衰老细胞，以及化生丛状样细胞与化生主细胞样细胞，经常共同定位于同一病变内。我们研究了与高级别病变相关的化生细胞类型，发现 Muc4、Lcn2 和 Cd274 的表达增加，突出了可能驱动恶性过程的基因。此外，我们发现了高度富集特定化生细胞类型的生态位（niches），并在这些区域内识别出了免疫细胞。我们检测到化生未定型细胞与免疫抑制性中性粒细胞之间，以及化生衰老细胞与巨噬细胞亚群之间存在密切的相互作用。结论：我们的研究结果表明，在癌症发生的早期阶段，化生细胞能以特定方式对免疫细胞进行重编程，从而在特定的生态位内支持免疫抑制微环境的形成。

### 第二部分 AI 大师评价

该研究利用单细胞测序和空间转录组学技术，系统解析了胰腺癌前病变中腺泡化生细胞的空间分布规律及其与微环境的相互作用。研究揭示了化生细胞亚型并非随机分布，而是通过克隆增殖形成特定的半同质性生态位，并首次精准绘制了化生细胞与中性粒细胞及巨噬细胞之间的早期互作图谱。通过鉴定高级别病变中的关键驱动基因如Muc4和Cd274，该研究不仅深化了对胰腺癌早期演进机制的理解，还证明了肿瘤在极早期阶段即具备诱导免疫抑制环境的能力，为早期精准干预提供了重要理论依据。

---

## 2. 肝窦内皮细胞中 Integrin αV-YAP-CTGF 轴的激活促进肝纤维化，导致充血性肝病中的门静脉高压和肝脏癌变

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41758081)
**期刊：** Gastroenterology
**PMID：** 41758081
**DOI：** 10.1053/j.gastro.2025.11.014

### 第一部分 原文与翻译

**英文原标题：** Activation of the Integrin αV-YAP-CTGF Axis in Liver Sinusoidal Endothelial Cells Promotes Liver Fibrogenesis, Leading to Portal Hypertension and Liver Carcinogenesis in Congestive Hepatopathy.

> **英文摘要：**
> BACKGROUND & AIMS: Chronic liver congestion progresses to liver fibrosis, eventually leading to cirrhosis and cancer. This study aimed to elucidate the mechanism of congestive hepatopathy (CH), focusing on liver sinusoidal endothelial cells (LSECs). METHODS: Partial inferior vena cava ligation (pIVCL) was performed to induce hepatic congestion in mice. Single-cell RNA sequencing (scRNA-seq) was conducted on murine livers after pIVCL. Cells underwent hydrostatic pressure stimulation. scRNA-seq and spatial transcriptomics were performed on human livers from patients with Fontan-associated liver disease. RESULTS: The scRNA-seq analysis showed that the integrin signaling pathway and yes-associated protein (YAP) were activated in pericentral LSECs after pIVCL. The most upregulated gene in pericentral LSECs was connective tissue growth factor (CTGF). Hydrostatic pressure activated YAP through integrin αV, leading to the upregulation of CTGF and type IV collagen (COL4) expression in LSECs. LSEC-derived CTGF upregulated the type I collagen (COL1) and COL4 expression in hepatic stellate cells. CTGF knockout in endothelial cells ameliorated CH-induced liver fibrosis and portal hypertension and even suppressed liver tumorigenesis. Integrin αV inhibition alleviated CH-induced liver fibrosis and portal hypertension with the decreased expression of CTGF, COL4, and COL1. scRNA-seq and spatial transcriptomics of clinical Fontan-associated liver disease samples revealed YAP activation and CTGF upregulation in pericentral LSECs, potentially leading to increased COL4 expression in LSECs and increased COL1 expression in hepatic stellate cells as fibrosis progressed. CONCLUSIONS: CTGF induction in LSECs may play an upstream role in the fibrogenesis of CH. The integrin αV-YAP-CTGF axis in LSECs could be a potential therapeutic target for CH.

> **中文摘要：**
> 背景与目的：慢性肝淤血会进展为肝纤维化，最终导致肝硬化和癌症。本研究旨在阐明充血性肝病（CH）的发病机制，重点关注肝窦内皮细胞（LSECs）。方法：对小鼠进行下腔静脉部分结扎（pIVCL）以诱导肝淤血。对 pIVCL 之后的小鼠肝脏进行单细胞 RNA 测序（scRNA-seq）。细胞接受静水压刺激。对 Fontan 相关肝病患者的人类肝脏进行 scRNA-seq 和空间转录组学分析。结果：scRNA-seq 分析显示，pIVCL 后中央静脉周围的 LSECs 中整合素（integrin）信号通路和 Yes 相关蛋白（YAP）被激活。中央静脉周围 LSECs 中上调最明显的基因是结缔组织生长因子（CTGF）。静水压通过整合素 αV 激活 YAP，导致 LSECs 中 CTGF 和 IV 型胶原（COL4）表达上调。LSEC 来源的 CTGF 上调了肝星状细胞中 I 型胶原（COL1）和 COL4 的表达。内皮细胞中的 CTGF 敲除改善了 CH 诱导的肝纤维化和门静脉高压，甚至抑制了肝脏肿瘤的发生。整合素 αV 抑制减轻了 CH 诱导的肝纤维化和门静脉高压，并降低了 CTGF、COL4 和 COL1 的表达。临床 Fontan 相关肝病样本的 scRNA-seq 和空间转录组学分析显示，随着纤维化的进展，中央静脉周围 LSECs 中的 YAP 激活和 CTGF 上调，可能导致 LSECs 中 COL4 表达增加以及肝星状细胞中 COL1 表达增加。结论：LSECs 中的 CTGF 诱导可能在 CH 的纤维化过程中发挥上游作用。LSECs 中的 Integrin αV-YAP-CTGF 轴可能是 CH 的潜在治疗靶点。

### 第二部分 AI 大师评价

本研究深入探讨了充血性肝病（CH）导致肝纤维化及癌变的分子机制，发现静水压通过激活肝窦内皮细胞（LSECs）中的 Integrin αV-YAP-CTGF 信号轴，进而驱动肝星状细胞活化和细胞外基质沉积。研究通过小鼠模型、临床 Fontan 相关肝病样本及空间转录组学等多维度手段，证实了该通路在门静脉高压和肿瘤发生中的关键作用。该发现不仅揭示了机械压力转导在肝脏病理中的新路径，还为 CH 的精准治疗提供了潜在的干预靶点，具有显著的临床转化价值。

---

## 3. m5C修饰的tRF3b-Cys-23通过稳定RBM4抑制H3K18乳酸化从而抑制膀胱癌的恶性进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41757512)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41757512
**DOI：** 10.1002/advs.202522294

### 第一部分 原文与翻译

**英文原标题：** mC-Modified tRF3b-Cys-23 Suppresses Bladder Cancer Malignancy by Repressing H3K18 Lactylation via Stabilizing RBM4.

> **英文摘要：**
> The epigenetic modification of transfer RNA (tRNA) and tRNA-derived small RNAs (tsRNAs) is associated with the initiation and development of cancer. However, the biological role of mC-modified tsRNAs, especially in bladder cancer (BC), and their regulatory mechanisms remain unclear. Here, we identify a novel mC-modified tsRNA, mC-tRF3b-Cys-23 (mtRC), whose expression is significantly downregulated in both tumor tissues and urine samples of BC patients and is strongly negatively correlated with the malignant progression of bladder cancer. In vitro and in vivo functional experiments reveal that mtRC, but not its unmodified counterpart (tRC), exhibits a tumor-suppressive role. Furthermore, NOP2/Sun RNA methyltransferase 6 (NSUN6) regulates mtRC abundance and suppresses cell proliferation. Mechanistically, mtRC directly binds the oncosuppressor protein RNA-binding motif 4 (RBM4) and improves its stability by preventing RBM4 ubiquitination, thereby upregulating RBM4 protein levels. RBM4 reduces the levels of glycolytic genes and decreases glycolysis, thereby inhibiting histone H3 lysine 18 lactylation (H3K18la). This reduction in H3K18 lactylation attenuates the transcriptional activation of the downstream oncogenes IL1RAP and VASH2, thereby ultimately suppressing tumor malignancy in BC. Together, our results not only underscore the critical role of mtRC in BC but also unravel a novel and coherent regulatory signaling axis-mtRC/RBM4/H3K18la/IL1RAP&VASH2-that orchestrates BC malignancy, suggesting mtRC may serve as a candidate therapeutic target for BC treatment.

> **中文摘要：**
> 转运RNA (tRNA) 和 tRNA 衍生小 RNA (tsRNA) 的表观遗传修饰与癌症的发生和发展密切相关。然而，m5C 修饰的 tsRNA 特别是在膀胱癌 (BC) 中的生物学作用及其调节机制仍不清楚。在此，我们鉴定出一种新型 m5C 修饰的 tsRNA，即 m5C-tRF3b-Cys-23 (mtRC)，其在膀胱癌患者的肿瘤组织和尿液样本中均显著下调，且与膀胱癌的恶性进展呈强负相关。体外和体内功能实验表明，mtRC 而非其未修饰的对应物 (tRC) 表现出抑癌作用。此外，NOP2/Sun RNA 甲基转移酶 6 (NSUN6) 调节 mtRC 的丰度并抑制细胞增殖。机制上，mtRC 直接结合抑癌蛋白 RNA 结合基序 4 (RBM4)，通过阻止 RBM4 泛素化来提高其稳定性，从而上调 RBM4 蛋白水平。RBM4 降低糖酵解基因的水平并减少糖酵解，从而抑制组蛋白 H3 第 18 位赖氨酸乳酸化 (H3K18la)。这种 H3K18 乳酸化的减少削弱了下游癌基因 IL1RAP 和 VASH2 的转录激活，从而最终抑制膀胱癌的肿瘤恶性程度。总之，我们的研究结果不仅强调了 mtRC 在膀胱癌中的关键作用，还揭示了一条新型且连贯的调节信号轴——mtRC/RBM4/H3K18la/IL1RAP&VASH2——该轴调控着膀胱癌的恶性进展，表明 mtRC 可能作为膀胱癌治疗的候选受选治疗靶点。

### 第二部分 AI 大师评价

本文深入探讨了m5C修饰的tsRNA在膀胱癌中的表观遗传调控机制。研究通过临床样本验证和分子机制探索，首次确立了NSUN6/mtRC/RBM4/H3K18la这一精密的信号轴，揭示了mtRC通过稳定抑癌蛋白RBM4来抑制糖酵解及随后的组蛋白乳酸化，从而阻断促癌基因的转录。该研究不仅在生物学机制上具有创新性，且mtRC在尿液中的表达差异为其作为膀胱癌无创诊断标志物提供了极高的临床转化潜力。

---

## 4. CDK8通过磷酸化SOX2维持垂体腺瘤的干性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41748950)
**期刊：** Oncogene
**PMID：** 41748950
**DOI：** 10.1038/s41388-026-03710-2

### 第一部分 原文与翻译

**英文原标题：** CDK8 phosphorylates SOX2 to maintain stemness of pituitary adenoma.

> **英文摘要：**
> Pituitary adenomas (PAs) are intracranial tumours with severe clinical complications and increased morbidity. Stem cell-like characteristics play a crucial role in the initiation and progression of PAs. In this study, we identified CDK8 as a critical regulator of stemness in PA tumorigenesis. Immunohistochemical analysis demonstrated that CDK8 expression is elevated in clinical PA samples and correlates significantly with Knosp grades, indicating its potential role in parasellar invasion. Inhibition of CDK8 significantly impaired the self-renewal capacity of patient-derived PA stem-like cells (PASCs), as evidenced by reduced tumoursphere formation. To elucidate the underlying mechanism, we found that CDK8 phosphorylates the pluripotency transcription factor SOX2, thereby disrupting its interaction with the E3 ubiquitin ligase HERC5 and preventing SOX2 degradation through the ubiquitin-proteasome pathway. Moreover, pharmacological inhibition of CDK8 markedly suppressed PA cell proliferation and viability in GH3 and MMQ cell lines, primary human PA cells, and murine xenograft models. These findings revealed a novel regulatory mechanism of PA stemness and provided a promising therapeutic target for PA.

> **中文摘要：**
> 垂体腺瘤（PAs）是伴有严重临床并发症和高发病率的颅内肿瘤。类干细胞特性在PAs的发生和进展中发挥着至关重要的作用。在本研究中，我们将CDK8鉴定为PA肿瘤发生中干性的关键调节因子。免疫组化分析显示，CDK8在临床PA样本中的表达水平升高，且与Knosp分级显著相关，表明其在鞍旁侵袭中具有潜在作用。抑制CDK8显著损害了患者来源的PA类干细胞（PASCs）的自我更新能力，表现为肿瘤球形成减少。为了阐明潜在机制，我们发现CDK8能够磷酸化多能转录因子SOX2，从而破坏其与E3泛素连接酶HERC5的相互作用，并防止SOX2通过泛素-蛋白酶体途径降解。此外，药理学抑制CDK8在GH3和MMQ细胞系、原代人PA细胞以及小鼠异种移植模型中均显著抑制了PA细胞的增殖和活力。这些发现揭示了一种新的PA干性调节机制，并为PA提供了一个具有前景的治疗靶点。

### 第二部分 AI 大师评价

本研究深入探讨了CDK8在垂体腺瘤（PA）干性维持中的分子机制，结合临床样本分析、PASCs细胞实验及异种移植模型进行了多维度验证。研究核心发现CDK8通过磷酸化SOX2蛋白，阻断其与E3泛素连接酶HERC5的结合，从而规避了泛素-蛋白酶体途径介导的降解，实现了SOX2蛋白的稳定及肿瘤干性的维持。该研究不仅揭示了CDK8-SOX2信号轴在PA侵袭性进展中的关键角色，还证明了药理学抑制CDK8的抗肿瘤有效性，为临床治疗侵袭性垂体腺瘤提供了极具潜力的分子靶点。

---

## 5. 癌症中 PTCH1 C 末端结构域的部分截短通过非经典激活 GLI-PI3K 环路促进肿瘤发生

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41748949)
**期刊：** Oncogene
**PMID：** 41748949
**DOI：** 10.1038/s41388-026-03698-9

### 第一部分 原文与翻译

**英文原标题：** Partial truncation of the C-terminal domain of PTCH1 in cancer promotes tumourigenesis by non-canonical activation of a GLI-PI3K loop.

> **英文摘要：**
> Loss of function mutations of the Hedgehog receptor PTCH1 are oncogenic drivers in some skin and brain cancers. We recently reported mutations in exons encoding the C-terminal tail of PTCH1 in colon cancer, which result in premature truncation but do not impair canonical Hedgehog signalling. In this study, we show that colon cancer cells engineered by CRISPR/Cas9 to express endogenous truncated PTCH1 have enhanced proliferation, colony formation, anchorage-independent growth and form larger tumours in vivo than isogenic cells expressing wild-type PTCH1. Analysis of the mechanisms underlying this growth advantage revealed profound transcriptional changes and unexpectedly, upregulation of GLI1 and GLI2 by a Smoothened-independent route, which proved to be necessary for the proliferative advantage. Furthermore, we found that truncation of PTCH1 C-tail upregulated several cancer-related pathways, including EGFR and Ras signalling and led to enhanced GLI-dependent PI3K activation, which exerted a positive feedback regulation on GLI expression and activity. Accordingly, PTCH1 mutant cells were highly sensitive to PI3K and GLI inhibitors and were only partially sensitive to EGFR and MEK inhibitors. Altogether, these findings reveal that PTCH1 C-tail truncating mutations promote colon cancer tumourigenesis through a non-canonical GLI-PI3K positive loop.

> **中文摘要：**
> Hedgehog 受体 PTCH1 的功能缺失突变是某些皮肤癌和脑癌的致癌驱动因素。我们最近报道了结肠癌中编码 PTCH1 C 末端尾部的外显子突变，这些突变导致过早截短，但并不损害经典的 Hedgehog 信号传导。在本研究中，我们展示了通过 CRISPR/Cas9 技术改造以表达内源性截短型 PTCH1 的结肠癌细胞，与表达野生型 PTCH1 的同源细胞相比，具有增强的增殖、克隆形成、非贴壁依赖性生长能力，并在体内形成更大的肿瘤。对这种生长优势背后机制的分析揭示了深刻的转录变化，并且出人意料地发现 GLI1 和 GLI2 通过一种独立于 Smoothened 的途径上调，这被证明是增殖优势所必需的。此外，我们发现 PTCH1 C 尾部的截短上调了包括 EGFR 和 Ras 信号传导在内的几种癌症相关通路，并导致增强的 GLI 依赖性 PI3K 激活，从而对 GLI 的表达和活性产生正反馈调节。因此，PTCH1 突变细胞对 PI3K 和 GLI 抑制剂高度敏感，而对 EGFR 和 MEK 抑制剂仅部分敏感。总而言之，这些发现揭示了 PTCH1 C 尾部截短突变通过非经典的 GLI-PI3K 正向反馈环路促进结肠癌的肿瘤发生。

### 第二部分 AI 大师评价

本研究揭示了结肠癌中 PTCH1 基因 C 末端截短突变的一种全新的非经典致癌机制，挑战了该基因仅通过经典 Hedgehog 信号通路发挥作用的传统观念。研究人员利用 CRISPR/Cas9 基因编辑技术证实，这种特定截短突变通过独立于 Smoothened 的途径激活 GLI 蛋白，并与 PI3K 通路形成正反馈环路，从而显著增强肿瘤细胞的恶性表型。该发现不仅深化了对 PTCH1 结构与功能关系的理解，还为携带此类突变的患者指明了 PI3K 和 GLI 抑制剂联合治疗的精准医学方向，具有重要的临床转化价值。

---

## 6. 超灵敏 CAR-T 细胞可消除小鼠体内难治性肿瘤

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41748887)
**期刊：** Nature
**PMID：** 41748887
**DOI：** 10.1038/d41586-026-00622-9

### 第一部分 原文与翻译

**英文原标题：** Ultra-sensitive CAR T cells eliminate hard-to-treat tumours in mice.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本研究报道了一种新型超灵敏 CAR-T 细胞的设计方案，通过优化受体信号传导机制，显著提升了细胞对低密度抗原的识别与杀伤能力。该技术在小鼠模型中成功消除了以往难以应对的难治性肿瘤，有效克服了传统 CAR-T 疗法在低抗原表达肿瘤中的有效性瓶颈。这一创新为扩大细胞免疫疗法的适应症范围，特别是在异质性较高的实体瘤治疗领域，提供了极具潜力的技术路径。

---

## 7. 遗传性癌症综合征的预防性疫苗

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41748757)
**期刊：** Nature medicine
**PMID：** 41748757
**DOI：** 10.1038/s41591-026-04248-2

### 第一部分 原文与翻译

**英文原标题：** Preventive vaccines for hereditary cancer syndromes.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

这篇文章重点探讨了针对遗传性癌症综合征开发预防性疫苗的新兴领域，旨在通过免疫干预降低高风险个体的癌症发生率。该研究方向体现了从治疗性疫苗向精准预防性疫苗转变的前沿思路，尤其对于携带特定胚系突变的人群具有重要临床意义。由于目前尚无详细摘要，推测其核心创新点在于筛选特异性免疫原以激发长期保护性免疫。此类研究的局限性通常在于临床试验周期长且需解决不同遗传背景下的免疫应答差异问题。

---

## 8. 突变型SRSF2相关的红细胞生成受损是由FYN错误剪接导致的mTORC1信号增强所介导的

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41748695)
**期刊：** Leukemia
**PMID：** 41748695
**DOI：** 10.1038/s41375-026-02892-8

### 第一部分 原文与翻译

**英文原标题：** Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicing.

> **英文摘要：**
> Somatic mutations in RNA splicing regulators, including the serine/arginine-rich protein SRSF2, are frequently observed in myeloid malignancies. Using mouse models and primary human samples, we investigated the impact of SRSF2 mutations on erythropoiesis. We found reduced erythropoiesis in Srsf2 versus wild-type mice upon stress-induced erythropoiesis and identified that SRSF2 mutations correlate with reduced hemoglobin in JAK2-mutant patients with myeloproliferative neoplasms (MPN). Consistent with this, Jak2-Srsf2 versus Jak2 mice displayed reduced red blood cell counts and erythroid precursor frequencies. RNA-sequencing on erythroid precursors showed reduced expression of heme metabolism and mitotic spindle-related genes, and increased expression of mTORC1 signaling in Srsf2 versus wild-type cells. RNA splicing analyses on the same cells and on human patient samples identified aberrant FYN splicing in SRSF2 cells, with increased aberrant FYNB over normal FYNT transcripts. FYNB, but not FYNT, expression resulted in reduced erythroid differentiation and increased phosphorylation of mTORC1 downstream target S6. Additionally, increased S6 phosphorylation was confirmed in primary Srsf2 erythroid cells. mTORC1 pathway inhibition using rapamycin normalized FYNB- and Srsf2-induced impaired erythropoiesis and significantly increased erythroid colony formation of SRSF2-mutant myelodysplastic neoplasm (MDS) bone marrow cells. Our data reveal targetable molecular mechanisms of impaired erythropoiesis in SRSF2-mutant cells.

> **中文摘要：**
> RNA剪接调节因子（包括富含丝氨酸/精氨酸的蛋白SRSF2）的体细胞突变在骨髓恶性肿瘤中频繁观察到。利用小鼠模型和原代人类样本，我们研究了SRSF2突变对红细胞生成的影响。我们发现，在应激诱导的红细胞生成过程中，Srsf2小鼠较野生型小鼠的红细胞生成减少，并发现SRSF2突变与JAK2突变的骨髓增殖性肿瘤（MPN）患者血红蛋白水平降低相关。与此一致的是，Jak2-Srsf2小鼠较Jak2小鼠表现出红细胞计数和红系前体频率降低。红系前体的RNA测序显示，与野生型细胞相比，Srsf2细胞中血红素代谢和有丝分裂纺锤体相关基因的表达降低，而mTORC1信号通路的表达增加。对相同细胞和人类患者样本的RNA剪接分析发现，SRSF2细胞中存在FYN剪接异常，表现为异常的FYNB转录本较正常的FYNT转录本增加。FYNB（而非FYNT）的表达导致红系分化减少，并增加了mTORC1下游靶点S6的磷酸化。此外，在原代Srsf2红系细胞中证实了S6磷酸化的增加。使用雷帕霉素抑制mTORC1通路可使FYNB和Srsf2诱导的红细胞生成受损恢复正常，并显著增加SRSF2突变型骨髓增殖异常肿瘤（MDS）骨髓细胞的红系集落形成。我们的数据揭示了SRSF2突变细胞中红细胞生成受损的可靶向分子机制。

### 第二部分 AI 大师评价

本研究深入探讨了SRSF2突变导致红细胞生成障碍的分子机制。研究通过整合转录组测序与临床样本分析，首次揭示了FYN基因的异常剪接（FYNB异构体增加）是驱动mTORC1信号通路过度激活、进而抑制红系分化的核心环节。实验证明，利用雷帕霉素抑制mTORC1通路可有效逆转这一病理过程，为SRSF2突变相关的骨髓增殖性肿瘤及骨髓增生异常综合征患者的贫血治疗提供了新的精准靶向策略。研究证据链完整，从基础模型到临床验证，具有较强的临床转化潜力。

---

## 9. 激光间质热疗联合辅助帕博利珠单抗治疗复发性高级别星形细胞瘤：一项1期/随机2b期试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41748622)
**期刊：** Nature communications
**PMID：** 41748622
**DOI：** 10.1038/s41467-026-69522-w

### 第一部分 原文与翻译

**英文原标题：** Laser interstitial thermal therapy and adjuvant pembrolizumab in recurrent high-grade astrocytoma: a Phase 1/randomized Phase 2b trial.

> **英文摘要：**
> Immune checkpoint inhibitors (ICIs) show minimal efficacy in recurrent high-grade astrocytoma (rHGA). Laser interstitial thermal therapy (LITT), a minimally invasive cytoreductive approach, may prime rHGA for ICI response. A phase 1/randomized phase 2b trial (ClinicalTrials.gov: NCT02311582 ) was designed to test pembrolizumab in combination with LITT in patients with rHGA. Nine patients were enrolled in the phase I dose-escalation lead-in study. No dose-limiting toxicities were observed and 200 mg of pembrolizumab every three weeks was determined as the recommended phase 2 dose. The phase 2b study was initially designed to randomize (up to 45) patients 1:1 to either LITT followed by pembrolizumab (LITT + PEM) or non-LITT surgery followed by pembrolizumab (NLS + PEM). Phase 2's primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), safety, and immune signature. After 21 patients, based on an independent Data and Safety Monitoring Committee request of unscheduled interim review of accumulating efficacy data, randomization stopped as benefit from NLS + PEM appeared limited, and the subsequent 24 patients received LITT + PEM. The pre-specified study endpoints were achieved. Among 39 per-protocol patients, LITT + PEM (n = 33) improved median OS (11.8 versus 5.2 months) and 18-month survival (42% versus 0%) compared to NLS + PEM (n = 6) (hazard ratio [HR] 0.17; 95% confidence interval [CI], 0.06-0.49; P = 0.0002). Median PFS was longer in LITT + PEM (4.5 versus 1.6 months; HR 0.21; 95% CI, 0.08-0.56; P = 0.0006). In an intent-to-treat sensitivity analysis (n = 21), OS (HR 0.29; 95% CI, 0.10-0.88) and PFS (HR 0.30; 95% CI, 0.10-0.87) again favored LITT + PEM (n = 13). Treatment was well tolerated. LITT activated non-classical monocytes, and pembrolizumab unleashed CD8⁺ T cell proliferation, clonal expansion, and coordinated memory T-cell responses. Overall, LITT + PEM is safe and may overcome rHGA immunosuppression to generate antitumor immunity.

> **中文摘要：**
> 免疫检查点抑制剂 (ICIs) 在复发性高级别星形细胞瘤 (rHGA) 中的疗效微乎其微。激光间质热疗 (LITT) 作为一种微创减瘤方法，可能诱导 rHGA 对 ICI 产生反应。本研究设计了一项 1 期/随机 2b 期试验 (ClinicalTrials.gov: NCT02311582)，旨在测试帕博利珠单抗联合 LITT 治疗 rHGA 患者的效果。9 名患者入组了 1 期剂量递增导入研究。未观察到剂量限制性毒性，确定每三周 200 mg 帕博利珠单抗为推荐的 2 期剂量。2b 期研究最初设计为将最多 45 名患者按 1:1 随机分配至 LITT 后接帕博利珠单抗组 (LITT + PEM) 或非 LITT 手术后接帕博利珠单抗组 (NLS + PEM)。2 期研究的主要终点是无进展生存期 (PFS)；次要终点包括总生存期 (OS)、安全性和免疫特征。在入组 21 名患者后，根据独立数据与安全监测委员会对累积疗效数据进行非计划中期审查的要求，由于 NLS + PEM 的获益似乎有限，随机化停止，随后 24 名患者均接受了 LITT + PEM。研究达到了预设终点。在 39 名符合方案的患者中，与 NLS + PEM (n = 6) 相比，LITT + PEM (n = 33) 显著改善了中位 OS（11.8 个月对 5.2 个月）和 18 个月生存率（42% 对 0%）（风险比 [HR] 0.17；95% 置信区间 [CI]，0.06-0.49；P = 0.0002）。LITT + PEM 组的中位 PFS 也更长（4.5 个月对 1.6 个月；HR 0.21；95% CI，0.08-0.56；P = 0.0006）。在意向性治疗敏感性分析 (n = 21) 中，OS (HR 0.29; 95% CI, 0.10-0.88) 和 PFS (HR 0.30; 95% CI, 0.10-0.87) 再次证实 LITT + PEM (n = 13) 更具优势。治疗耐受性良好。机制研究显示，LITT 激活了非典型单核细胞，而帕博利珠单抗触发了 CD8⁺ T 细胞增殖、克隆扩增和协调的记忆 T 细胞反应。总体而言，LITT + PEM 方案安全，并可能克服 rHGA 的免疫抑制以产生抗肿瘤免疫。

### 第二部分 AI 大师评价

本研究通过1/2b期临床试验探索了激光间质热疗（LITT）联合帕博利珠单抗治疗复发性高级别星形细胞瘤的新路径。研究发现，LITT不仅能发挥微创减瘤作用，还能通过激活单核细胞与免疫检查点抑制剂产生协同效应，显著延长患者的OS和PFS。尽管因中期分析显示对照组获益有限而提前终止随机化导致样本量分布不均，但其展示的强大生存获益和明确的免疫激活机制，为难治性神经胶质瘤的综合治疗提供了重要的高质量循证依据。

---

## 10. 一种具有内在佐剂性的工程化线性非帽依赖型 mRNA 疫苗诱导小鼠产生强效抗肿瘤免疫

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41748617)
**期刊：** Nature communications
**PMID：** 41748617
**DOI：** 10.1038/s41467-026-69972-2

### 第一部分 原文与翻译

**英文原标题：** An engineered linear cap-independent mRNA vaccine with intrinsic adjuvanticity induces potent anti-tumor immunity in mice.

> **英文摘要：**
> mRNA cancer vaccines demonstrate potential in clinical trials, but existing platforms struggle to boost antitumor efficacy without added cost or complexity. Here, we present a streamlined linear cap-independent mRNA (LciRNA) cancer vaccine platform, achieved by fusing a UPA protective sequence, composed of a viral exoribonuclease-resistant RNA (xrRNA) and a poly(A) binding protein (PABP) motif, to an optimized Enterovirus A internal ribosome entry site. UPA impedes exonuclease-mediated decay and recruits RNA-binding proteins to stabilize LciRNA, enabling stable in vivo expression without 5' capping or modifications. Moreover, LciRNA innately stimulates immune responses by engaging pattern-recognition receptors, promoting dendritic cell maturation, and upregulating proinflammatory signals. In murine melanoma and HPV-associated tumor models, this vaccine platform elicits strong systemic and intra-tumoral T cell responses, achieving superior tumor control, demonstrating how immune stimulation-translation synergy underpins its efficacy. Thus, we present a cost-effective platform with enhanced efficacy, and highlight coupled immune stimulation and translation as a paradigm for future mRNA cancer vaccines.

> **中文摘要：**
> mRNA 癌症疫苗在临床试验中展现出潜力，但现有平台在不增加成本或复杂性的情况下，难以进一步提升抗肿瘤功效。在此，我们提出了一种精简的线性非帽依赖型 mRNA（LciRNA）癌症疫苗平台，该平台通过将由病毒外切核酸酶抗性 RNA（xrRNA）和多聚腺苷酸结合蛋白（PABP）基序组成的 UPA 保护序列，融合到优化的 A 型肠道病毒内部核糖体进入位点（IRES）中而实现。UPA 能够阻碍外切核酸酶介导的降解，并招募 RNA 结合蛋白来稳定 LciRNA，从而能够在无需 5' 加帽或碱基修饰的情况下实现稳定的体内表达。此外，LciRNA 通过结合模式识别受体、促进树突状细胞成熟以及上调促炎信号，能够先天性地刺激免疫反应。在小鼠黑色素瘤和 HPV 相关肿瘤模型中，该疫苗平台诱导了强烈的全身及肿瘤内 T 细胞反应，实现了卓越的肿瘤控制，证明了免疫刺激与翻译的协同作用是其疗效的核心支撑。因此，我们展示了一个高成本效益且效能增强的平台，并强调了免疫刺激与翻译的耦合可作为未来 mRNA 癌症疫苗的设计范式。

### 第二部分 AI 大师评价

本研究开发了一种创新的线性非帽依赖型 mRNA（LciRNA）平台，通过引入 UPA 保护序列克服了传统 mRNA 疫苗依赖 5' 加帽和核苷修饰导致的生产成本高、工艺复杂等瓶颈。该系统不仅大幅增强了 mRNA 在体内的稳定性和翻译效率，还赋予了疫苗独特的内在免疫佐剂活性，能够协同激活先天性和特异性免疫反应。在多种小鼠模型中展现出的强效抗肿瘤活性，证明了这种“翻译-免疫刺激耦合”策略的先进性，为开发下一代低成本、高效率的 mRNA 肿瘤疫苗提供了重要的工程化思路。

---

## 11. SETD2介导的组蛋白H3第36位赖氨酸三甲基化（H3K36me3）重塑肠干细胞表观遗传图谱，以协调脂质代谢并减轻细胞衰老

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41748592)
**期刊：** Cell death & disease
**PMID：** 41748592
**DOI：** 10.1038/s41419-026-08518-2

### 第一部分 原文与翻译

**英文原标题：** Histone 3 lysine 36 trimethylation by SETD2 shapes an epigenetic landscape in intestinal stem cells to orchestrate lipid metabolism and attenuate cell senescence.

> **英文摘要：**
> The self-renewal capacity of intestinal stem cells (ISCs) declines with aging, leading to a loss of homeostasis and an increased susceptibility to intestinal diseases. Despite the established significance of lipid metabolism and epigenetic regulation in ISC function, the molecular mechanisms that connect these processes to aging-related ISC dysfunction remain elusive. Here, we hypothesize that histone 3 lysine 36 trimethylation (H3K36me3) might act as a bridge between these processes. In this study, we demonstrate that H3K36me3 caused by SETD2 is critical for ISC stemness. H3K36me3 deficiency results in reduced ISC proliferation and differentiation, disrupts fatty acid oxidation (FAO), and promotes ISC senescence. Mechanistically, the loss of H3K36me3 triggers the activity of the SWI/SNF chromatin remodeling complex and leads to increased chromatin accessibility and enhancer activation, which alters FAO- and senescence-related gene expression. Importantly, our data demonstrate that metabolic intervention can prevent the senescence of ISC due to H3K36me3 deficiency. Our findings reveal a crucial role for H3K36me3 in maintaining the epigenetic landscape that orchestrates FAO and determines intestinal stem cell functions, emphasizing the role of FAO as a key modulator between H3K36me3 and ISC aging, suggesting that metabolic intervention may help mitigate age-related ISC dysfunction.

> **中文摘要：**
> 肠干细胞 (ISCs) 的自我更新能力随年龄增长而下降，导致稳态丧失及肠道疾病易感性增加。尽管脂质代谢和表观遗传调节在 ISC 功能中的重要性已得到公认，但连接这些过程与衰老相关 ISC 功能障碍的分子机制仍不清楚。在这里，我们假设组蛋白 H3 第 36 位赖氨酸三甲基化 (H3K36me3) 可能是连接这些过程的桥梁。在本研究中，我们证明由 SETD2 产生的 H3K36me3 对 ISC 的干性至关重要。H3K36me3 缺失会导致 ISC 增殖和分化减少，破坏脂肪酸氧化 (FAO)，并促进 ISC 衰老。从机制上讲，H3K36me3 的缺失会触发 SWI/SNF 染色质重塑复合物的活性，并导致染色质可及性增加和增强子激活，从而改变 FAO 和衰老相关基因的表达。重要的是，我们的数据表明，代谢干预可以防止由于 H3K36me3 缺失导致的 ISC 衰老。我们的研究结果揭示了 H3K36me3 在维持表观遗传图谱中的关键作用，该图谱协调 FAO 并决定肠干细胞功能，强调了 FAO 作为 H3K36me3 与 ISC 衰老之间的关键调节因子，并提示代谢干预可能有助于减轻与年龄相关的 ISC 功能障碍。

### 第二部分 AI 大师评价

本研究系统阐明了SETD2介导的H3K36me3修饰在维持肠干细胞（ISC）稳态中的核心作用，揭示了其作为表观遗传信号与脂质代谢之间协同作用的关键纽带。研究发现H3K36me3缺失会通过募集SWI/SNF复合物重塑染色质可及性，进而抑制脂肪酸氧化（FAO）并驱动细胞衰老。该研究不仅揭示了ISC衰老的分子机制，还创新性地提出通过代谢干预逆转表观遗传缺陷导致的干细胞功能衰退，为延缓肠道衰老提供了重要的转化医学靶点。

---

## 12. 肿瘤来源循环肿瘤DNA分层评估肛门鳞状细胞癌的复发风险与生存期

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41748568)
**期刊：** Nature communications
**PMID：** 41748568
**DOI：** 10.1038/s41467-026-69984-y

### 第一部分 原文与翻译

**英文原标题：** Tumor-informed circulating tumor DNA stratifies recurrence risk and survival in anal squamous cell carcinoma.

> **英文摘要：**
> Patients with anal squamous cell carcinoma (ASCC) who fail chemoradiation (CRT) have poor outcomes, underscoring the need for biomarkers to guide risk stratification. In a real-world two-center cohort of 84 adults with non-metastatic ASCC treated with curative-intent CRT, we prospectively evaluate a tumor-informed circulating tumor DNA (ctDNA) assay (Signatera, Natera). Here we show that across 647 plasma specimens, ctDNA is positive at pre-treatment in 79% (61/77), including 89% (24/27) with stage III disease. End-of-treatment ctDNA positivity identifies patients with inferior one-year outcomes: 63% overall survival, 44% progression-free survival, and 39% locoregional failure. Conversely, patients who were ctDNA-negative at baseline or who cleared ctDNA during-treatment have 100% locoregional failure-free survival. During surveillance, ctDNA re-emergence precedes clinical or radiographic relapse in every case. These findings support the consideration of ctDNA as a dynamic, treatment-responsive biomarker warranting prospective validation for risk-adapted surveillance and adjuvant therapy in ASCC.

> **中文摘要：**
> 肛门鳞状细胞癌（ASCC）在放化疗（CRT）失败后的患者预后较差，这凸显了对指导风险分层的生物标志物的需求。在一项包含84名接受根治性放化疗的非转移性ASCC成人的真实世界双中心队列研究中，我们前瞻性地评估了肿瘤来源的循环肿瘤DNA（ctDNA）检测（Signatera, Natera）。我们在此展示，在647份血浆标本中，治疗前的ctDNA阳性率为79%（61/77），其中III期疾病患者的阳性率为89%（24/27）。治疗结束时的ctDNA阳性识别出一年预后较差的患者：总生存率为63%，无进展生存率为44%，局部区域衰竭率为39%。相反，基线ctDNA阴性或在治疗期间ctDNA转阴的患者，其无局部区域衰竭生存率为100%。在随访期间，所有病例中ctDNA的再次出现均先于临床或影像学复发。这些发现支持将ctDNA视为一种动态的、具有治疗反应性的生物标志物，值得在ASCC的风险适应性随访和辅助治疗中进行前瞻性验证。

### 第二部分 AI 大师评价

该研究通过双中心前瞻性队列评估了ctDNA检测在非转移性ASCC中的临床价值，其核心发现在于ctDNA状态与患者预后的强相关性。研究不仅证实了治疗结束时ctDNA阳性是预测复发和低生存率的关键指标，更强调了ctDNA转阴对预示长期生存的价值。创新性地展示了ctDNA重现先于放射学复发的特征，为未来基于生物标志物的ASCC个体化治疗和动态随访策略提供了重要依据。

---

## 13. 利用小分子稳定剂 rezatapopt 靶向 p53 癌症突变体 Y220C、Y220N 和 Y220S

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41748563)
**期刊：** Cell death & disease
**PMID：** 41748563
**DOI：** 10.1038/s41419-026-08492-9

### 第一部分 原文与翻译

**英文原标题：** Targeting the p53 cancer mutants Y220C, Y220N, and Y220S with the small-molecule stabilizer rezatapopt.

> **英文摘要：**
> The cavity-creating p53 cancer mutation Y220C, which accounts for an estimated 125,000 new cancer cases per year, serves as an excellent paradigm for the development of mutant p53 reactivators. Several molecules that reactivate this thermolabile cancer mutant by targeting the mutation-induced crevice have been developed, and one of them, rezatapopt, is currently in clinical trials. The less frequently occurring Y220N and Y220S mutations are even more destabilizing than Y220C but create a similar surface crevice, raising the question of whether cancer patients with these mutations might also benefit from rezatapopt treatment. Here, we show that rezatapopt also binds to the Y220N and Y220S mutants, with nanomolar affinity, resulting in a full recovery of wild-type-like stability for the latter. High-resolution crystal structures of all three mutants bound to rezatapopt revealed a conserved binding mode, highlighting key interactions, including multipolar interactions of a fluorine substituent at a chiral center with the protein backbone. Consistent with the biophysical and structural data, rezatapopt reactivated p53 signaling in both Y220C and Y220S mutant cells by restoring the folded conformation and transcriptional activity, leading to anti-proliferative effects and apoptosis, albeit requiring higher compound concentrations in Y220S cells. The Y220N mutant, despite exhibiting high-nanomolar affinity for rezatapopt and substantial stabilization, did not show noticeable effects in cells at the concentrations tested, as rezatapopt binding resulted in only partial compensation for the mutation-induced loss of stability, for which we provide a structural explanation. Our data suggest that the development of clinical pan-Y220C/N/S reactivators, which could benefit an additional 10,000 patients per year, is challenging but not impossible.

> **中文摘要：**
> 能够产生空腔的 p53 癌症突变 Y220C 每年约导致 125,000 例新增癌症病例，是开发突变型 p53 再激活剂的绝佳范式。目前已经开发出几种通过靶向突变诱导的缝隙来再激活这种热不稳定性癌症突变的分子，其中之一 rezatapopt 目前正处于临床试验阶段。发生频率较低的 Y220N 和 Y220S 突变比 Y220C 具有更强的不稳定性，但会产生类似的表面缝隙，这引发了携带这些突变的癌症患者是否也能从 rezatapopt 治疗中获益的问题。在本文中，我们证明了 rezatapopt 也能以纳摩尔级的亲和力结合 Y220N 和 Y220S 突变体，并使后者的稳定性完全恢复到野生型水平。所有三种突变体与 rezatapopt 结合的高分辨率晶体结构揭示了一种保守的结合模式，突出了关键的相互作用，包括手性中心氟取代基与蛋白质骨架的多极相互作用。与生物物理和结构数据一致，rezatapopt 通过恢复折叠构象和转录活性，在 Y220C 和 Y220S 突变细胞中重新激活了 p53 信号传导，从而产生抗增殖效应并诱导细胞凋亡，尽管在 Y220S 细胞中需要更高的化合物浓度。尽管 Y220N 突变体对 rezatapopt 表现出高纳摩尔级的亲和力并获得了显著的稳定性提升，但在所测试的浓度下，细胞实验并未显示出明显效果，因为 rezatapopt 的结合仅能部分补偿突变引起的稳定性损失，对此我们从结构学角度给出了合理解释。我们的数据表明，开发临床通用的 p53 Y220C/N/S 再激活剂虽然具有挑战性，但并非不可能实现，这可能会使每年额外增加的 10,000 名患者受益。

### 第二部分 AI 大师评价

该研究系统评估了临床阶段药物 rezatapopt 对 p53 不同 Y220 位点突变体（C、N、S）的靶向效力。通过整合结构生物学、生物物理学和细胞功能实验，研究揭示了该药对 Y220C 和 Y220S 具有显著的再激活作用，但对 Y220N 的细胞内疗效有限，并从分子结构层面阐明了这种差异性。该成果不仅为 rezatapopt 的适应症扩展提供了科学依据，也为设计更广谱的 p53 突变稳定剂提供了重要的结构优化方向。

---

## 14. PD-1通过调节TCR和CD28信号通路保护扩增中的人类T细胞免受过早的再刺激诱导的细胞死亡

**原文链接：** [点击跳转](https://pubmed.ncbi.gov/41748562)
**期刊：** Cell death & disease
**PMID：** 41748562
**DOI：** 10.1038/s41419-026-08530-6

### 第一部分 原文与翻译

**英文原标题：** PD-1 protects expanding human T cells from premature restimulation-induced cell death by modulating TCR and CD28 signaling.

> **英文摘要：**
> Programmed cell death-1 (PD-1) is a co-inhibitory receptor expressed on T cells that dampens TCR and CD28 signaling in the immunological synapse. PD-1 is significantly upregulated on T cells in the tumor microenvironment, where it promotes exhaustion in the context of chronic antigen restimulation. Exhaustion renders T cells hyporesponsive and ineffectual, but potentially resistant to restimulation-induced cell death (RICD). Restimulation-induced cell death (RICD) is a critical propriocidal apoptosis program triggered in activated T cells upon robust TCR re-engagement, which serves to constrain effector T cell expansion and longevity to prevent collateral tissue damage. While the checkpoint function of PD-1 has profound implications for cancer immunotherapy, the role of PD-1 in regulating newly activated T cells remains unclear. We hypothesized that PD-1 attenuates RICD sensitivity in human effector T cells by modulating TCR signal strength. Here we show that transient upregulation of PD-1 helps to protect clonally expanding human CD4+ and CD8 + T cells from premature RICD, with only moderate protection noted in terminally-differentiated, PD-1 effector CD8 + T cells. Restimulation of T cells with beads containing PD-L1 results in significant apoptosis resistance, dependent on PD-L1 dosage and the proximity of PD-L1 to the TCR and CD28. Interestingly, PD-L1 demonstrated a more significant RICD rescue with CD28 co-ligation as opposed to TCR engagement alone, suggesting PD-1 signaling targets both signaling pathways in this context. Furthermore, biochemical/proteomic data suggest PD-1 modulates proximal signaling downstream of both TCR and CD28 and influences the expression of specific pro/anti-apoptotic proteins that govern RICD sensitivity. Despite the original assumption of PD-1 as a programmed death-inducing protein, our research reveals that homeostatic expression of PD-1 in clonally expanding T cells confers RICD resistance that promotes T cell survival and persistence. These findings present significant implications for understanding how blocking or engaging the PD-L1:PD-1 signaling axis may influence apoptosis sensitivity in both normal and exhausted T cells to alter adaptive immune responses.

> **中文摘要：**
> 程序性死亡受体-1 (PD-1) 是一种表达在T细胞上的共抑制受体，能够减弱免疫突触中的TCR和CD28信号。在肿瘤微环境中，PD-1在T细胞上显著上调，并在慢性抗原再刺激的背景下促进细胞耗竭。耗竭使T细胞呈现低反应性且无效，但也可能使其对再刺激诱导的细胞死亡 (RICD) 产生抗性。RICD是一种关键的自杀性凋亡程序，在活化的T细胞受到强烈的TCR再次结合时触发，其作用是限制效应T细胞的扩增和寿命，以防止附带的组织损伤。虽然PD-1的检查点功能对癌症免疫治疗具有深远影响，但PD-1在调节新活化T细胞中的作用仍不明确。我们假设PD-1通过调节TCR信号强度来降低人类效应T细胞对RICD的敏感性。本研究表明，PD-1的瞬时上调有助于保护克隆扩增中的人类CD4+和CD8+ T细胞免受过早的RICD，而在终末分化的PD-1效应CD8+ T细胞中仅观察到适度的保护作用。利用含有PD-L1的磁珠再刺激T细胞会导致显著的凋亡抗性，这取决于PD-L1的剂量以及PD-L1与TCR和CD28的接近程度。有趣的是，与单纯的TCR结合相比，PD-L1在CD28共连接的情况下表现出更显著的RICD挽救作用，表明在这种背景下PD-1信号同时靶向这两个信号通路。此外，生化与蛋白质组学数据表明，PD-1调节TCR和CD28下游的近端信号，并影响控制RICD敏感性的特定促/抗凋亡蛋白的表达。尽管最初认为PD-1是一种诱导程序性死亡的蛋白，但我们的研究揭示，克隆扩增T细胞中PD-1的稳态表达赋予了其RICD抗性，从而促进了T细胞的存活和持久性。这些发现对于理解阻断或激活PD-L1:PD-1信号轴如何通过改变正常和耗竭T细胞的凋亡敏感性来影响适应性免疫反应具有重要意义。

### 第二部分 AI 大师评价

该研究挑战了PD-1仅作为“死亡诱导蛋白”的传统观点，揭示了其在T细胞扩增早期通过调节TCR/CD28信号强度来拮抗再刺激诱导的细胞死亡（RICD）的新机制。通过生化与蛋白质组学分析，作者证明了PD-1的稳态表达对维持效应T细胞的存活与持久性至关重要。这一发现不仅深化了对免疫检查点生理功能的理解，也为解析癌症免疫治疗中PD-1抑制剂对T细胞稳态的影响提供了重要理论支撑。

---

## 15. 肿瘤相关 CD19 巨噬细胞诱导肝细胞癌中的免疫抑制微环境

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41748561)
**期刊：** Nature communications
**PMID：** 41748561
**DOI：** 10.1038/s41467-026-69638-z

### 第一部分 原文与翻译

**英文原标题：** Tumor-associated CD19 macrophages induce immunosuppressive microenvironment in hepatocellular carcinoma.

> **英文摘要：**
> Tumor-associated macrophages are a key component that contributes to the immunosuppressive microenvironment in human cancers. However, therapeutic targeting of macrophages has been a challenge in clinic due to the limited understanding of their heterogeneous subpopulations and distinct functions. Here, we identify a clinically relevant CD19 subpopulation of macrophages that is enriched in many types of cancer, particularly in hepatocellular carcinoma (HCC). The CD19 macrophages exhibit increased levels of programmed cell death 1 ligand 1 (PD-L1) and CD73, enhanced mitochondrial oxidation, and compromised phagocytosis, indicating their immunosuppressive functions. Targeting CD19 macrophages with anti-CD19+ chimeric antigen receptor T (CAR-T) cells inhibited HCC tumor growth. We identify Paired Box 5 (PAX5) as a primary driver of up-regulated mitochondrial biogenesis in CD19 macrophages, which depletes cytoplasmic Ca, leading to lysosomal deficiency and consequent accumulation of CD73 and PD-L1. Inhibiting CD73 or mitochondrial oxidation enhanced the efficacy of immune checkpoint blockade therapy in treating HCC, suggesting great promise for CD19 macrophage-targeting therapeutics.

> **中文摘要：**
> 肿瘤相关巨噬细胞是导致人类癌症免疫抑制微环境的关键组成部分。然而，由于对其异质性亚群和独特功能了解有限，针对巨噬细胞的治疗靶向在临床上一直是一项挑战。在此，我们鉴定出一种具有临床相关性的 CD19 巨噬细胞亚群，该亚群在多种类型的癌症中富集，尤其是在肝细胞癌（HCC）中。CD19 巨噬细胞表现出程序性细胞死亡 1 配体 1 (PD-L1) 和 CD73 水平升高、线粒体氧化增强以及吞噬作用减弱，表明其具有免疫抑制功能。利用抗 CD19 嵌合抗原受体 T (CAR-T) 细胞靶向 CD19 巨噬细胞可抑制 HCC 肿瘤生长。我们鉴定出配对盒蛋白 5 (PAX5) 是 CD19 巨噬细胞中线粒体生物合成上调的主要驱动因子，这会消耗胞浆钙（Ca），导致溶酶体缺陷以及随之而来的 CD73 和 PD-L1 积累。抑制 CD73 或线粒体氧化增强了免疫检查点阻断疗法治疗 HCC 的疗效，这为靶向 CD19 巨噬细胞的治疗提供了巨大前景。

### 第二部分 AI 大师评价

本研究揭示了肝细胞癌中一种特异性的 CD19 巨噬细胞亚群，并系统阐明了其通过 PAX5 驱动的线粒体代谢重塑诱导免疫抑制的分子机制。研究发现该亚群通过耗竭胞浆钙离子导致溶酶体功能障碍，进而促进 PD-L1 和 CD73 的积累。创新性地提出利用抗 CD19 CAR-T 细胞及联合代谢干预来打破免疫抑制，为克服 HCC 免疫治疗耐药提供了极具临床转化潜力的靶向策略。

---

## 16. ROR1-PI3K/AKT信号通路驱动TP53突变型卵巢癌对细胞周期阻滞的适应性耐药

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41748546)
**期刊：** Cell death & disease
**PMID：** 41748546
**DOI：** 10.1038/s41419-026-08501-x

### 第一部分 原文与翻译

**英文原标题：** ROR1-PI3K/AKT signaling drives adaptive resistance to cell cycle blockade in TP53 mutated ovarian cancer.

> **英文摘要：**
> Drug resistance remains a major challenge to durable responses in ovarian cancer, the fifth leading cause of cancer-related death among women. In this study, we developed long-term resistant (lt-res, several months) pre-clinical models of two drugs inducing mitotic arrest in TP53-mutated cells: adavosertib (ADA), an investigational WEE1 inhibitor targeting the DNA damage response and currently evaluated in clinical trials, and paclitaxel (PTX), a widely used chemotherapeutic agent in cancer care targeting microtubules. Through integrated multi-omics functional profiling, we identify a shared PI3K/AKT-regulated signaling node that governs drug adaptation across all lt-res models. This node modulates the activity of DNA-damage responses and genotoxic stress to toggle between two adaptive states: activated PI3K/AKT driving a proliferative "fast-bypass" program with sustained cell cycle progression and mitotic evasion, or reduced PI3K/AKT signaling initiating a "slow-repair" state characterized by DNA damage checkpoint engagement, replication slowdown, and increased drug efflux. Notably, upregulation of receptor tyrosine kinases, such as ROR1, was observed in both ADA and PTX lt-res models with activated PI3K/AKT signaling. Targeting ROR1 with zilovertamab-vedotin, a monoclonal antibody-drug conjugate, resulted in enhanced cytotoxicity, demonstrating a new approach against recurrent drug-resistant ovarian cancer.

> **中文摘要：**
> 耐药性仍然是实现卵巢癌持久疗效的主要挑战，卵巢癌是女性癌症相关死亡的第五大原因。在这项研究中，我们针对在TP53突变细胞中诱导有丝分裂停滞的两种药物，开发了长期耐药（lt-res，数月）的临床前模型：一种是正在进行临床评估、针对DNA损伤反应的在研WEE1抑制剂adavosertib (ADA)；另一种是广泛用于癌症治疗、针对微管的化疗药物紫杉醇 (PTX)。通过整合多组学功能图谱分析，我们发现了一个受PI3K/AKT调节的共有信号节点，该节点控制着所有长期耐药模型中的药物适应。该节点通过调节DNA损伤反应和基因毒性应激的活性，在两种适应状态之间切换：激活的PI3K/AKT驱动“快速旁路”程序，表现为持续的细胞周期进展和有丝分裂逃逸；或降低的PI3K/AKT信号启动“慢速修复”状态，其特征是DNA损伤检查点参与、复制减缓和药物外排增加。值得注意的是，在PI3K/AKT信号激活的ADA和PTX长期耐药模型中，均观察到了受体酪氨酸激酶（如ROR1）的上调。使用单克隆抗体-药物偶联物zilovertamab-vedotin靶向ROR1可增强细胞毒性，这为治疗复发性耐药卵巢癌提供了一种新方法。

### 第二部分 AI 大师评价

该研究深入探讨了TP53突变型卵巢癌对WEE1抑制剂（ADA）和紫杉醇（PTX）产生耐药的分子机制，揭示了ROR1-PI3K/AKT信号通路在其中的核心驱动作用。研究通过多组学分析揭示了耐药细胞在“快速旁路”和“慢速修复”两种适应性状态间切换的生物学特性。其创新性在于发现了ROR1作为耐药的关键节点，并证明了抗体偶联药物（ADC）zilovertamab-vedotin在克服这种适应性耐药方面的潜力，为复发耐药卵巢癌的精准治疗提供了新策略。

---

## 17. RRM1 抑制增强了肺腺癌对地西他滨治疗的敏感性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41748545)
**期刊：** Cell death & disease
**PMID：** 41748545
**DOI：** 10.1038/s41419-026-08522-6

### 第一部分 原文与翻译

**英文原标题：** RRM1 inhibition sensitizes lung adenocarcinoma to decitabine treatment.

> **英文摘要：**
> Aberrant DNA methylation has been implicated in tumorigenesis and the development of lung cancer. However, Nucleoside analog DNA methyltransferase inhibitors have demonstrated clinical utility in the treatment of myelodysplastic syndrome and acute myeloid leukemia; the drugs have not shown commensurate clinical efficacy in solid tumors. Mechanisms mediating the primary resistance to DNA hypomethylating agents in solid tumors are not fully understood. Here, we hypothesized that factors that limit incorporation of nucleoside analog DNA methyltransferase inhibitors in genomic DNA may underlie the tumor cell intrinsic primary resistance to decitabine (DAC) in lung cancer. We found that RRM1 expression levels were inversely correlated with DAC incorporation rates detected by LC-MS/MS. RNA interference-mediated depletion of RRM1, the catalytic subunit of ribonucleotide reductase (RNR), or pharmacological inhibition of RNR significantly potentiated inhibition of lung cancer cell clonogenic survival in vitro and xenograft growth in vivo by DAC treatment. Additionally, RRM1 inhibition enhances DAC-mediated tumor suppressor gene reactivation and STING pathway activation via DNA damage-induced IFI16 sensing. RNR inhibition led to increased incorporation of DAC into genomic DNA by reducing the availability of dCTP. These findings nominate the promising combination therapy of DAC and RNR inhibitors as being ripe for further clinical translation.

> **中文摘要：**
> 异常的 DNA 甲基化与肺癌的发生和发展密切相关。然而，尽管核苷类似物 DNA 甲基转移酶抑制剂在治疗骨髓增生异常综合征和急性髓系白血病中显示出临床效用，但这些药物在实体瘤中并未表现出相应的临床疗效。目前，介导实体瘤对 DNA 低甲基化药物产生原发性耐药的机制尚未完全明确。在此，我们假设限制核苷类似物 DNA 甲基转移酶抑制剂整合进基因组 DNA 的因素，可能是肺癌细胞对地西他滨（DAC）产生内在原发性耐药的基础。我们发现，通过 LC-MS/MS 检测到的 DAC 整合率与 RRM1 的表达水平呈负相关。通过 RNA 干扰耗竭核糖核苷酸还原酶（RNR）的催化亚基 RRM1，或通过药理学手段抑制 RNR，均能显著增强 DAC 治疗在体外对肺癌细胞克隆原生存的抑制作用，以及在体内对异种移植瘤生长的抑制作用。此外，RRM1 抑制通过 DNA 损伤诱导的 IFI16 感知，增强了 DAC 介导的抑癌基因重新激活和 STING 通路的激活。RNR 抑制通过减少 dCTP 的可用性，导致 DAC 向基因组 DNA 的整合增加。这些发现表明，DAC 与 RNR 抑制剂的联合疗法极具前景，值得进一步开展临床转化。

### 第二部分 AI 大师评价

该研究深入探讨了肺腺癌对地西他滨（DAC）产生原发性耐药的分子机制。研究者通过 LC-MS/MS 等严谨的实验手段发现，RRM1 介导的 dCTP 水平升高是限制 DAC 进入基因组的关键屏障。研究不仅揭示了 RRM1 抑制通过增强 DNA 损伤和激活 STING 通路来协同 DAC 发挥作用的机制，还为克服实体瘤对表观遗传药物耐药提供了极具临床转化潜力的联合用药策略。

---

## 18. UBE3A介导的mH2A1泛素化激活TERT转录以促进胰腺癌的衰老抗性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41748542)
**期刊：** Cell death & disease
**PMID：** 41748542
**DOI：** 10.1038/s41419-026-08480-z

### 第一部分 原文与翻译

**英文原标题：** UBE3A-mediated mH2A1 Ubiquitination activates TERT transcription to promote senescence resistance in pancreatic cancer.

> **英文摘要：**
> Pancreatic cancer is a highly aggressive tumor with a poor prognosis. The ubiquitin-proteasome system is crucial in maintaining protein homeostasis and regulating cellular senescence, thereby influencing tumorigenesis and progression; however, the specific mechanisms underlying this process remain unclear. Ubiquitin protein ligase E3A (UBE3A) is associated with various tumors; however, its potential role in pancreatic cancer warrants further investigation. The effects of UBE3A on cellular senescence were evaluated through in vitro and in vivo experiments, including SA-β-gal staining, EdU assays, detection of senescence-associated markers, and the establishment of subcutaneous xenograft and liver metastasis models. Mechanistic studies utilized Ub-MS, IP-MS, ChIP-seq, and RNA-seq to explore downstream pathways, followed by validation through ubiquitination assays, ChIP-qPCR, and dual-luciferase reporter assays. Our results showed that UBE3A was significantly upregulated in pancreatic cancer tissues and correlated with poor patient outcomes. Functional studies have demonstrated that UBE3A inhibits cellular senescence in pancreatic cancer cells, thereby promoting tumor proliferation and metastasis. Mechanistically, the histone variant macroH2A1 (mH2A1) recruits EZH2 to mediate H3K27me3 modification, repressing Telomerase reverse transcriptase (TERT) transcription. UBE3A interacts with mH2A1 through its N-terminal domain, leading to K48-linked polyubiquitination at the K167 residue, which accelerates mH2A1 degradation and upregulates TERT, enhancing the anti-senescence capacity of pancreatic cancer cells. Inhibition of UBE3A combined with the senolytic agent ABT‑263 induced apoptosis and inhibited tumor growth. The UBE3A/mH2A1/TERT axis enhances the anti-senescence capacity of pancreatic cancer cells and drives malignant progression, suggesting that UBE3A may serve as a novel therapeutic target for pancreatic cancer.

> **中文摘要：**
> 胰腺癌是一种极具侵袭性且预后较差的肿瘤。泛素-蛋白酶体系统在维持蛋白质稳态和调节细胞衰老中至关重要，从而影响肿瘤的发生和发展；然而，这一过程背后的具体机制仍不清楚。泛素蛋白连接酶 E3A (UBE3A) 与多种肿瘤相关；然而，其在胰腺癌中的潜在作用仍需进一步研究。通过体外和体内实验评估了 UBE3A 对细胞衰老的影响，包括 SA-β-gal 染色、EdU 实验、衰老相关标志物的检测，以及建立皮下异种移植和肝转移模型。机制研究利用 Ub-MS、IP-MS、ChIP-seq 和 RNA-seq 探索下游通路，随后通过泛素化检测、ChIP-qPCR 和双荧光素酶报告实验进行验证。我们的结果显示，UBE3A 在胰腺癌组织中显著上调，并与患者的不良预后相关。功能研究表明，UBE3A 抑制胰腺癌细胞中的细胞衰老，从而促进肿瘤增殖和转移。从机制上讲，组蛋白变体 macroH2A1 (mH2A1) 招募 EZH2 介导 H3K27me3 修饰，从而抑制端粒酶逆转录酶 (TERT) 的转录。UBE3A 通过其 N 端结构域与 mH2A1 相互作用，导致 K167 位点发生 K48 连锁的多泛素化，从而加速 mH2A1 的降解并上调 TERT，增强胰腺癌细胞的抗衰老能力。抑制 UBE3A 联合衰老清除药物 ABT-263 可诱导凋亡并抑制肿瘤生长。UBE3A/mH2A1/TERT 轴增强了胰腺癌细胞的抗衰老能力并驱动恶性进展，表明 UBE3A 可能作为胰腺癌的新型治疗靶点。

### 第二部分 AI 大师评价

该研究深入探讨了泛素连接酶 UBE3A 在胰腺癌逃避细胞衰老中的分子机制。研究团队通过多组学技术（Ub-MS 和 ChIP-seq）发现 UBE3A 能介导组蛋白变体 mH2A1 的 K48 连锁泛素化降解，从而解除其对 TERT 转录的抑制，增强肿瘤细胞的衰老抗性并促进转移。该研究不仅揭示了 UBE3A/mH2A1/TERT 这一全新的调控轴，还通过联合 UBE3A 抑制剂与衰老清除剂（Senolytics）展示了潜在的治疗策略，具有较强的科研创新性和临床转化指导意义。

---

## 19. 利用类器官共培养技术研究癌症相关成纤维细胞与肿瘤细胞相互作用的研究进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41748541)
**期刊：** Cell death & disease
**PMID：** 41748541
**DOI：** 10.1038/s41419-026-08512-8

### 第一部分 原文与翻译

**英文原标题：** The research advances of crosstalk between cancer-associated fibroblasts and tumor cells using co-culture organoids.

> **英文摘要：**
> Cancer-associated fibroblasts (CAFs) fundamentally impact on characteristics of tumor cells and are concerned with therapy resistance via extensive interplay with cancer cells and other stromal components. In addition, inherent plasticity and multifunctionality of CAFs enable cancer cells to cultivate them, leading to dynamic changes in the population of CAFs in a context-dependent manner. Despite CAFs have long been regarded as a key participant in cancer development and therefore an appealing therapeutic target, most clinical trials targeting CAFs end in failure, and even accelerate progression of cancers, indicating that dynamic complicated identity and function of CAFs far exceed the current view. Accordingly, analyzing the heterogeneous subgroups and different functions of CAFs in a context dependent mode is of great significance. To ascertain the functional interactions between CAFs and cancer cells, various three-dimensional co-culture models of organoid with CAFs and cancer cells from murine or human have been successfully established. In the review, we recapitulate the proposed methods for cultivating organoids consisted of tumor cells and CAFs as well as molecular mechanisms involving in regulating variety of CAF subgroups. Current strategies targeting tumor-promoting CAFs selectively are also discussed, offering perception and perspectives for scientific investigation and clinical trials concerning various methods targeting CAFs.

> **中文摘要：**
> 癌症相关成纤维细胞 (CAFs) 从根本上影响肿瘤细胞的特性，并通过与癌细胞及其他基质成分的广泛相互作用参与治疗耐药。此外，CAFs 固有的塑性和多功能性使癌细胞能够对其进行驯化，从而导致 CAF 群体以环境依赖的方式发生动态变化。尽管长期以来 CAFs 被认为是癌症发展的关键参与者，因而是极具吸引力的治疗靶点，但大多数针对 CAFs 的临床试验均以失败告终，甚至加速了癌症进展，这表明 CAFs 动态复杂的身份和功能远超当前的认识。因此，以环境依赖模式分析 CAFs 的异质性亚群及不同功能具有重要意义。为了探究 CAFs 与癌细胞之间的功能相互作用，已成功建立多种源自小鼠或人类的 CAFs 与癌细胞类器官三维共培养模型。在本综述中，我们总结了由肿瘤细胞和 CAFs 组成的类器官培养方法，以及涉及调节多种 CAF 亚群的分子机制。同时，本文还讨论了当前选择性靶向促肿瘤 CAF 的策略，为针对 CAFs 的各种方法的科学研究和临床试验提供了见解和展望。

### 第二部分 AI 大师评价

本综述重点关注了癌症相关成纤维细胞（CAF）与肿瘤细胞在类器官模型中的动态相互作用，阐述了CAF在肿瘤耐药性和异质性中的核心作用。文章深入剖析了CAF靶向药物临床试验失败的深层原因，强调了基于环境依赖性分析CAF亚群的重要性。通过总结先进的三维类器官共培养技术及分子调控机制，该综述为开发选择性靶向促肿瘤CAF的新型治疗方案提供了重要的理论支撑，具有较高的临床转化参考价值。

---

## 20. 乌苯美司通过竞争性结合LAP3与UBE3A，在胃癌中与PD-L1阻断产生协同作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41748538)
**期刊：** Cell death & disease
**PMID：** 41748538
**DOI：** 10.1038/s41419-026-08509-3

### 第一部分 原文与翻译

**英文原标题：** Ubenimex synergizes with the PD-L1 blockade in gastric cancer by competitively binding LAP3 with UBE3A.

> **英文摘要：**
> Immune checkpoint inhibitors (ICIs), particularly PD-1/PD-L1 blockade, represent a cornerstone of treatment for advanced gastric cancer (GC). However, their clinical efficacy is hampered by low response rates and the development of both primary and acquired resistance, underscoring the need for innovative combination therapies. In this study, we investigate the potential of Ubenimex, an immunomodulator and inhibitor of leucyl aminopeptidase 3 (LAP3), in enhancing the therapeutic efficacy of PD-L1 blockade in GC. Using a syngeneic GC mouse model, we demonstrate that Ubenimex significantly augments the efficacy of anti-PD-L1 therapy. We further explore the role of LAP3 in GC progression and find that it is highly expressed in both GC tissues and cells, with elevated LAP3 levels correlating with poor prognosis. Functionally, LAP3 facilitates immune evasion through impaired CD8 T cell infiltration and cytotoxicity in the GC tumor microenvironment (TME). Notably, our findings reveal that LAP3 enhances PD-L1 expression by binding to UBE3A, an E3 ubiquitin ligase. Ubenimex disrupts the LAP3-UBE3A interaction, leading to restored UBE3A-mediated ubiquitination and degradation of PD-L1. This mechanism reinvigorates CD8 T cell infiltration and cytotoxic activity within the TME, thereby overcoming resistance to anti-PD-L1 therapy. In conclusion, our study provides a strong rationale for the synergistic potential of Ubenimex in combination with PD-1/PD-L1 blockade, offering a promising strategy to overcome current limitations of ICIs therapy in GC patients.

> **中文摘要：**
> 免疫检查点抑制剂（ICIs），特别是PD-1/PD-L1阻断，代表了晚期胃癌（GC）治疗的基石。然而，它们的临床疗效受到低反应率以及原发性和获得性耐药性发展的阻碍，这强调了对创新联合疗法的需求。在本研究中，我们探讨了乌苯美司（Ubenimex，一种免疫调节剂和亮氨酰氨基肽酶3 [LAP3] 抑制剂）在增强胃癌中PD-L1阻断疗效方面的潜力。通过利用同基因胃癌小鼠模型，我们证明了乌苯美司能显著增强抗PD-L1治疗的功效。我们进一步探索了LAP3在胃癌进展中的作用，并发现其在胃癌组织和细胞中均呈高表达，且LAP3水平升高与预后不良相关。在功能上，LAP3通过损害胃癌肿瘤微环境（TME）中的CD8 T细胞浸润和细胞毒性来促进免疫逃逸。值得注意的是，我们的研究结果揭示，LAP3通过结合E3泛素连接酶UBE3A来增强PD-L1的表达。乌苯美司破坏了LAP3-UBE3A的相互作用，从而恢复了UBE3A介导的PD-L1泛素化和降解。这一机制重新激活了TME内的CD8 T细胞浸润和细胞毒活性，从而克服了对抗PD-L1疗法的耐药性。总之，我们的研究为乌苯美司与PD-1/PD-L1阻断联合应用的协同潜力提供了强有力的理论依据，为克服目前胃癌患者ICI治疗的局限性提供了一种有前景的策略。

### 第二部分 AI 大师评价

本研究揭示了乌苯美司通过调控LAP3/UBE3A/PD-L1轴增强胃癌免疫治疗的新机制。研究发现LAP3通过竞争性结合泛素连接酶UBE3A来抑制PD-L1的降解，导致免疫逃逸，而乌苯美司作为LAP3抑制剂能有效阻断该相互作用，促进PD-L1降解并激活TME内的抗肿瘤免疫反应。该研究不仅深化了对胃癌免疫耐药机制的理解，还通过“老药新用”的策略为提高PD-1/PD-L1阻断剂在胃癌中的临床响应率提供了极具转化潜力的实验依据。

---

## 21. 锌依赖性转录后调控在酒精相关性肝病肝细胞命运及再生中的作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41748158)
**期刊：** Gut
**PMID：** 41748158
**DOI：** 10.1136/gutjnl-2025-337941

### 第一部分 原文与翻译

**英文原标题：** Zinc-dependent post-transcriptional control of hepatocyte fate in and regeneration of alcohol-associated liver disease.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本研究聚焦于锌元素在酒精相关性肝病（ALD）中对肝细胞命运及肝脏再生的转录后调控机制。研究深入探讨了微量元素如何作为关键的信号节点，在非基因组层面精准干预酒精损伤后的组织修复过程。这一发现不仅丰富了营养因子与复杂分子调控网络交互作用的理论基础，也为以锌稳态为靶点的肝再生治疗策略提供了重要启示。鉴于其发表于消化病学领域顶级期刊《Gut》，该研究在揭示代谢性肝病细胞命运决定方面具有极高的学术价值。

---

## 22. 胶质母细胞瘤分泌的 C1QL1 协调肿瘤微管扩张和神经突触修剪，以驱动恶性突触形成和复发

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41747254)
**期刊：** Cancer discovery
**PMID：** 41747254
**DOI：** 10.1158/2159-8290.CD-25-1123

### 第一部分 原文与翻译

**英文原标题：** Glioblastoma-secreted C1QL1 orchestrates tumor microtube expansion and neural synaptic pruning to drive malignant synapse formation and recurrence.

> **英文摘要：**
> Glioblastoma (GBM) cells form neuron-to-glioma malignant synapses on neurite-like tumor microtubes (TMs), driving infiltrative growth and recurrence. The mechanisms underlying coordinated crosstalk among GBM cells and with neurons to favor malignant over normal synapses remain largely unknown. Here, we demonstrate that glioma-secreted C1QL1 is a key messenger for glioma-neuron and glioma-glioma crosstalk to drive TM expansion and malignant synapse formation. C1QL1 binds to its receptor BAI3 on neighboring neurons and GBM cells, activating Rac1-mediated cytoskeleton rearrangement to prune normal synapses and outgrow TMs, promoting malignant synapse and glioma network formation. Targeted treatment with a non-GEF-targeting, first-in-class Rac1 inhibitor rescues C1QL1-mediated synaptic pruning, inhibiting TMs and malignant synapses to impede glioma recurrence. Our findings elucidate how crosstalk among GBM cells and neurons allows infiltrating GBM cells to sculpt and integrate into the existing neural network, highlighting a therapeutic strategy against GBM recurrence through simultaneous inhibition of TMs and glioma-induced synaptic pruning.

> **中文摘要：**
> 胶质母细胞瘤（GBM）细胞在类神经突状的肿瘤微管（TMs）上形成神经元-胶质瘤恶性突触，驱动其浸润性生长和复发。GBM 细胞之间以及其与神经元之间协调相互作用以使恶性突触优先于正常突触形成的潜在机制在很大程度上仍不为人知。在此，我们证明了胶质瘤分泌的 C1QL1 是胶质瘤-神经元和胶质瘤-胶质瘤交流的关键信使，驱动 TMs 扩张和恶性突触形成。C1QL1 与邻近神经元和 GBM 细胞上的受体 BAI3 结合，激活 Rac1 介导的细胞骨架重排，从而修剪正常突触并促进 TMs 生长，推动恶性突触和胶质瘤网络的形成。使用非 GEF 靶向的、同类首创（first-in-class）的 Rac1 抑制剂进行靶向治疗，可挽救 C1QL1 介导的突触修剪，通过抑制 TMs 和恶性突触形成来阻碍胶质瘤复发。我们的研究结果阐明了 GBM 细胞与神经元之间的相互作用如何使浸润的 GBM 细胞雕刻并整合到现有的神经网络中，突显了通过同时抑制 TMs 和胶质瘤诱导的突触修剪来对抗 GBM 复发的治疗策略。

### 第二部分 AI 大师评价

本研究深入揭示了胶质母细胞瘤（GBM）分泌蛋白 C1QL1 在重构肿瘤微环境中的核心作用，发现其通过 BAI3/Rac1 信号通路不仅促进了肿瘤微管的扩张，还通过修剪正常神经突触来实现肿瘤对神经网络的深度整合。该研究的创新之处在于阐明了 GBM 如何通过主动“重塑”现有神经环路来支持自身的恶性生长，并验证了新型 Rac1 抑制剂在阻断肿瘤复发中的潜力。这一发现为针对胶质瘤网络化浸润的神经科学疗法提供了重要的理论依据和干预靶点。

---

## 23. 通过肿瘤微环境调节因子的体内CRISPR激活筛选实现免疫基因疗法组合的合理设计

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41747251)
**期刊：** Cancer discovery
**PMID：** 41747251
**DOI：** 10.1158/2159-8290.CD-25-0545

### 第一部分 原文与翻译

**英文原标题：** Rational design of immune gene therapy combinations via in vivo CRISPR activation screen of tumor microenvironment modulators.

> **英文摘要：**
> The hostile tumor microenvironment (TME) remains a major challenge for cancer immunotherapy. Here, we performed TME-targeted in vivo CRISPR activation (CRISPRa) screen to identify factors that promote anti-tumor immunity, culminating in rationally designed immune gene therapy combinations. Multiplexed activation of genes encoding antigen presentation, T cell proliferation, co-stimulation, and migration (APCM) leads to enhanced anti-tumor responses. An APCM-focused CRISPRa screen in metastatic tumors identified CD80, TNFSF14, CXCL10, TNFSF18, TNFSF9, and IFNG as top immunostimulatory candidates. Further optimization pinpointed TNFSF9 (4-1BBL) + IFNG + IL12B (4II) as a potent therapeutic combination. AAV-4II enhanced antigen presentation, T cell activation, proliferation, cytotoxicity, and tumor infiltration. Preconditioning the TME with AAV-4II synergized with CAR-T and TCR-T cell therapies to suppress primary and metastatic solid tumors in vivo. These findings establish TME-targeted CRISPRa screening as a rapid route to develop immune gene therapy combinations against solid tumors.

> **中文摘要：**
> 敌对的肿瘤微环境（TME）仍然是癌症免疫治疗面临的主要挑战。在本研究中，我们进行了针对TME的体内CRISPR激活（CRISPRa）筛选，以鉴定促进抗肿瘤免疫的因子，最终实现了合理设计的免疫基因疗法组合。对编码抗原提呈、T细胞增殖、共刺激和迁移（APCM）的基因进行多重激活，可增强抗肿瘤反应。在转移性肿瘤中进行的以APCM为重点的CRISPRa筛选鉴定了CD80、TNFSF14、CXCL10、TNFSF18、TNFSF9和IFNG作为主要的免疫刺激候选因子。进一步的优化确定了TNFSF9 (4-1BBL) + IFNG + IL12B (4II) 是一种强效的治疗组合。AAV-4II增强了抗原提呈、T细胞激活、增殖、细胞毒性和肿瘤浸润。使用AAV-4II预处理TME与CAR-T和TCR-T细胞疗法产生协同作用，在体内抑制了原发性和转移性实体瘤。这些发现确立了针对TME的CRISPRa筛选是开发针对实体瘤的免疫基因疗法组合的快速途径。

### 第二部分 AI 大师评价

本研究利用先进的体内CRISPRa筛选技术，在复杂的肿瘤微环境中系统性地鉴定了驱动抗肿瘤免疫的关键因子，并成功构建了基于AAV的高效免疫基因治疗组合4II（TNFSF9/IFNG/IL12B）。该方法的创新之处在于其“合理设计”理念，通过多重激活APCM通路显著增强了免疫细胞在实体瘤内的浸润与活性。研究不仅揭示了多种免疫调节因子的协同机制，还证明了该疗法在重塑微环境及协同细胞治疗（CAR-T/TCR-T）方面的强大潜力，为克服实体瘤免疫抑制屏障提供了极具临床转化价值的新策略。

---

## 24. 促肿瘤炎症性 SPP1+ 巨噬细胞-IL-6-CRP 轴驱动膀胱癌的免疫功能障碍

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41747249)
**期刊：** Cancer discovery
**PMID：** 41747249
**DOI：** 10.1158/2159-8290.CD-25-1774

### 第一部分 原文与翻译

**英文原标题：** A tumor-promoting inflammatory SPP1+ macrophage-IL-6-CRP axis drives immune dysfunction in bladder cancer.

> **英文摘要：**
> Immune checkpoint blockade (ICB) has revolutionized treatment for urothelial bladder cancer (UC), yet response rates remain limited. Inflammation promotes disease progression and treatment resistance, with macrophages shaping the tumor microenvironment (TME). While elevated blood C-reactive protein (CRP) associates with poor clinical outcomes in UC, its relationship to the TME remains unclear. Here, we show that elevated plasma IL-6 and CRP associate with increased tumor macrophage infiltration across multiple ICB-treated cohorts. Single-cell RNA sequencing of the largest UC atlas to date, integrated with bulk RNA sequencing, identifies enrichment of immunosuppressive SPP1+ macrophages in TMEs from patients with high plasma IL-6. Spatial and functional analyses demonstrate that SPP1+ macrophages suppress T cell activity partly via IL-6 signaling, whereas CXCL9+ macrophages promote T cell activation. These findings link systemic inflammation to local immune dysfunction and define a macrophage-driven axis associated with ICB resistance and therapeutic targets to improve immunotherapy outcomes in UC.

> **中文摘要：**
> 免疫检查点阻断（ICB）彻底改变了尿路上皮膀胱癌（UC）的治疗，但其缓解率仍然有限。炎症促进疾病进展和治疗耐药，而巨噬细胞塑造了肿瘤微环境（TME）。虽然血液中 C 反应蛋白（CRP）升高与 UC 的不良临床预后相关，但其与 TME 的关系仍不清楚。在此，我们展示了在多个接受 ICB 治疗的队列中，血浆 IL-6 和 CRP 升高与肿瘤巨噬细胞浸润增加相关。通过将迄今为止最大的 UC 单细胞 RNA 测序图谱与大批量（bulk）RNA 测序相结合，研究发现在血浆 IL-6 水平较高的患者 TME 中，免疫抑制性 SPP1+ 巨噬细胞显著富集。空间和功能分析表明，SPP1+ 巨噬细胞部分通过 IL-6 信号传导抑制 T 细胞活性，而 CXCL9+ 巨噬细胞则促进 T 细胞活化。这些发现将全身性炎症与局部免疫功能障碍联系起来，并定义了一个与 ICB 耐药相关的巨噬细胞驱动轴，为改善 UC 免疫治疗效果提供了治疗靶点。

### 第二部分 AI 大师评价

本研究通过整合大规模单细胞和本体转录组测序，揭示了系统性炎症指标（CRP/IL-6）与膀胱癌局部免疫抑制微环境之间的关键联系。研究明确了 SPP1+ 巨噬细胞通过 IL-6 信号通路抑制 T 细胞功能的机制，并将其与促进免疫活化的 CXCL9+ 巨噬细胞进行了对比。该成果为 ICB 耐药提供了系统的生物标志物解释，并确定了针对特定巨噬细胞亚群的潜在治疗靶点，具有极高的临床转化价值。

---

## 25. 基于循环GPNMB的多模态模型整合肿瘤-免疫互作以预测食管癌免疫治疗疗效

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41747244)
**期刊：** Cancer discovery
**PMID：** 41747244
**DOI：** 10.1158/2159-8290.CD-25-1907

### 第一部分 原文与翻译

**英文原标题：** A Circulating GPNMB-Based Multimodal Model Integrates Tumor-Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer.

> **英文摘要：**
> Neoadjuvant immunotherapy improves outcomes in esophageal squamous cell carcinoma (ESCC), yet ~70% of patients fail to respond. Pretreatment biopsies and plasma provide critical opportunities for biomarker discovery. Here, we performed plasma proteomic profiling and identified soluble glycoprotein non-metastatic melanoma protein B (sGPNMB) as the most elevated circulating protein in non-responders. Mechanistically, tumor cell-derived sGPNMB suppressed CD8+ T cell receptor (TCR) signaling via the SDC4-CD148 axis to induce functional exhaustion, with secretion being required for its immunosuppressive activity. Cancer-associated fibroblast-epithelial (CAF-Epi) niches promoted SOX2 upregulation in tumor cells, transcriptionally activating GPNMB expression. In humanized PDX models, circulating GPNMB levels predicted response to PD-1 blockade, and GPNMB inhibition synergised with therapy. Across retrospective cohorts and a prospective clinical trial, a multimodal model combining plasma GPNMB levels, CAF-Epi niche detection, and clinical-pathological features achieved robust predictive accuracy for immunotherapy response and survival. These findings establish a spatial-circulating biomarker framework for precision ESCC immunotherapy.

> **中文摘要：**
> 新辅助免疫治疗改善了食管鳞状细胞癌（ESCC）的预后，但约70%的患者仍无反应。治疗前活检和血浆为生物标志物的发现提供了关键机会。在此，我们进行了血浆蛋白质组学分析，并确定可溶性非转移性黑色素瘤糖蛋白B（sGPNMB）是无反应者中升高最明显的循环蛋白。从机制上看，肿瘤细胞来源的sGPNMB通过SDC4-CD148轴抑制CD8+ T细胞受体（TCR）信号传导，从而诱导功能耗竭，且分泌过程是其发挥免疫抑制活性所必需的。癌症相关成纤维细胞-上皮细胞（CAF-Epi）微环境促进了肿瘤细胞中SOX2的上调，进而在转录水平激活GPNMB的表达。在人源化PDX模型中，循环GPNMB水平预测了对PD-1阻断剂的反应，且抑制GPNMB可与治疗产生协同作用。在回顾性队列和一项前瞻性临床试验中，结合血浆GPNMB水平、CAF-Epi微环境检测和临床病理特征的多模态模型，对免疫治疗反应和生存期实现了稳健的预测准确性。这些发现为精准ESCC免疫治疗建立了一个空间-循环生物标志物框架。

### 第二部分 AI 大师评价

本研究通过血浆蛋白质组学鉴定出sGPNMB是预测食管鳞癌免疫治疗耐药的关键循环生物标志物，并深入揭示了CAF诱导的SOX2-GPNMB轴通过SDC4-CD148通路抑制T细胞功能的分子机制。研究通过整合循环蛋白、空间微环境及临床特征构建了多模态预测模型，并在前瞻性临床试验中证实了其卓越的预测准确性。该工作不仅为克服免疫耐药提供了潜在靶点，其提出的“空间-循环”联合预测框架也为肿瘤精准医学提供了创新的研究范式。

---

## 26. 整合体内与体外慢性筛选揭示 NFIL3 是 T 细胞功能障碍的驱动因子

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41747243)
**期刊：** Cancer discovery
**PMID：** 41747243
**DOI：** 10.1158/2159-8290.CD-25-1524

### 第一部分 原文与翻译

**英文原标题：** Integrated chronic in vivo and in vitro screens uncover NFIL3 as a driver of T cell dysfunction.

> **英文摘要：**
> CAR therapy has transformed the treatment landscape for hematological malignancies but its efficacy in solid tumors is limited, owing in part to insufficient functional persistence of the engineered T cells. To elucidate the basis for their functional decline, we conducted integrated chronic in vivo and in vitro screens of 400 transcription factors, which revealed NFIL3 as a driver of CAR T cell dysfunction. Genetic disruption of NFIL3 in CAR T cells sustains their expansion, increases cytokine production, overall restraining terminal differentiation. Loss of NFIL3 enhances CAR T cell efficacy, improving tumor control and prolonging survival in xenograft and syngeneic mouse tumor models across different CAR designs. Under chronic stimulation, disruption of NFIL3 establishes a transcriptional state predictive of favorable clinical outcomes. Our findings underscore the power of comprehensive in vivo genetic screens integrated with multi-parameter in vitro assessment and identify NFIL3 as a novel therapeutic target to enhance cancer immunotherapy.

> **中文摘要：**
> CAR 疗法已经改变了血液系统恶性肿瘤的治疗格局，但由于工程化 T 细胞的功能持久性不足等原因，其在实体瘤中的疗效受到限制。为了阐明 T 细胞功能衰退的基础，我们对 400 个转录因子进行了整合的体内和体外慢性筛选，结果揭示 NFIL3 是 CAR T 细胞功能障碍的驱动因素。在 CAR T 细胞中敲除 NFIL3 基因可以维持其扩增能力，增加细胞因子的产生，并从总体上抑制终末分化。NFIL3 的缺失增强了 CAR T 细胞的疗效，在不同 CAR 设计的异种移植和同基因小鼠肿瘤模型中改善了肿瘤控制并延长了生存期。在慢性刺激下，NFIL3 的破坏建立了一种可预测良好临床预后的转录状态。我们的研究结果强调了综合体内遗传筛选结合多参数体外评估的强大功能，并确定 NFIL3 是增强癌症免疫治疗的新型治疗靶点。

### 第二部分 AI 大师评价

该研究通过对400个转录因子进行创新的体内外整合高通量筛选，成功识别出驱动CAR-T细胞功能衰竭的关键因子NFIL3。研究利用多种小鼠肿瘤模型和基因编辑技术，系统论证了敲除NFIL3能够通过重塑转录状态、抑制终末分化来显著提升T细胞的扩增能力与抗肿瘤持久性。这一发现不仅揭示了T细胞耗竭的新型分子机制，也为克服实体瘤CAR-T疗法中常见的持久性瓶颈提供了具有临床转化潜力的靶向新策略。

---

## 27. 晚期胃食管癌的免疫治疗与靶向治疗：ASCO 指南更新

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41747202)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41747202
**DOI：** 10.1200/JCO-25-02958

### 第一部分 原文与翻译

**英文原标题：** Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update.

> **英文摘要：**
> PURPOSE: To provide updated recommendations for immunotherapy and targeted therapy for patients with advanced gastroesophageal cancer. METHODS: ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice. RESULTS: Twelve newly published or updated phase III randomized controlled trials met the inclusion criteria for the systematic review. RECOMMENDATIONS: The target population for these recommendations is patients with unresectable locally advanced, advanced, or metastatic gastroesophageal cancer. Results from testing for actionable biomarkers should be available as soon as possible to inform treatment decision making. Immunotherapy with doublet chemotherapy is recommended for patients with proficient mismatch repair (pMMR)/microsatellite stable (MSS) human epidermal growth factor receptor 2 (HER2)-negative gastroesophageal adenocarcinoma or squamous cell carcinoma and PD-L1 expression ≥1; patients with higher PD-L1 expression are more likely to benefit from immunotherapy. Zolbetuximab is recommended for patients with gastroesophageal adenocarcinoma, PD-L1 <1, and positive CLDN18.2 expression. Patients with dual PD-L1 and CLDN18.2 positivity should engage in shared decision making, considering the factors outlined in the guideline. Doublet chemotherapy alone is recommended for patients who are not positive for actionable biomarkers or are not considered candidates for targeted therapy or immunotherapy. For patients with pMMR/MSS HER2-positive gastric/gastroesophageal junction (GEJ) adenocarcinoma, trastuzumab and doublet chemotherapy is recommended; for patients with PD-L1 expression ≥1, the addition of pembrolizumab is recommended. Immunotherapy alone or with doublet chemotherapy is recommended for patients with mismatch repair deficient/microsatellite instability-high gastroesophageal cancer. Second-line therapy options include ramucirumab with paclitaxel, trastuzumab deruxtecan for HER2-positive gastric/GEJ adenocarcinoma, and immunotherapy for PD-L1 ≥1 esophageal squamous cell carcinoma after first-line combination chemotherapy without immunotherapy.Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines.

> **中文摘要：**
> 目的：为晚期胃食管癌患者的免疫治疗和靶向治疗提供最新的临床建议。方法：ASCO 召集了一个专家小组，对相关研究进行系统评价，并制定临床实践建议。结果：共有 12 项新发表或更新的 III 期随机对照试验符合系统评价的纳入标准。建议：本建议的目标人群是不可切除的局部晚期、晚期或转移性胃食管癌患者。应尽快获得可操作生物标志物的检测结果，以为治疗决策提供依据。对于错配修复功能完整（pMMR）/微卫星稳定（MSS）、人表皮生长因子受体 2（HER2）阴性且 PD-L1 表达 ≥1 的胃食管腺癌或鳞状细胞癌患者，建议采用免疫治疗联合双药化疗；PD-L1 表达越高，患者从免疫治疗中获益的可能性越大。对于胃食管腺癌、PD-L1 <1 且 CLDN18.2 表达阳性的患者，建议使用 Zolbetuximab。对于 PD-L1 和 CLDN18.2 双阳性的患者，应在考虑指南概述因素的基础上进行共同决策。对于生物标志物检测阴性或不适合接受靶向治疗/免疫治疗的患者，建议仅采用双药化疗。对于 pMMR/MSS、HER2 阳性的胃/胃食管结合部（GEJ）腺癌患者，建议采用曲妥珠单抗联合双药化疗；对于 PD-L1 表达 ≥1 的患者，建议增加帕博利珠单抗。对于错配修复缺陷/微卫星高度不稳定（dMMR/MSI-H）的胃食管癌患者，建议单独使用免疫治疗或联合双药化疗。二线治疗方案包括雷莫西尤单抗联合紫杉醇、针对 HER2 阳性胃/GEJ 腺癌的曲妥珠单抗原德鲁替康，以及在一线接受不含免疫治疗的联合化疗后，针对 PD-L1 ≥1 的食管鳞状细胞癌采用免疫治疗。更多信息请访问 www.asco.org/gastrointestinal-cancer-guidelines。

### 第二部分 AI 大师评价

该指南更新基于 12 项最新的 III 期临床试验结果，系统性地重塑了晚期胃食管癌的精准治疗路径。其核心贡献在于确立了基于 PD-L1、HER2、MSI/MMR 及新型标志物 CLDN18.2 的分层决策框架，特别是将 Zolbetuximab 纳入 PD-L1 阴性/CLDN18.2 阳性患者的推荐。尽管临床实施仍受限于生物标志物检测的时效性和药物可及性，但该指南显著提升了胃食管癌个体化治疗的规范性，是当前消化道肿瘤领域的权威诊疗标准。

---

## 28. 肝脏硬度通过 YAP/TAZ 介导代谢功能障碍相关脂肪性肝病中的肝内胆固醇蓄积

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41747066)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41747066
**DOI：** 10.1002/advs.202500379

### 第一部分 原文与翻译

**英文原标题：** Liver Stiffness Directs Intrahepatic Cholesterol Accumulation Through YAP/TAZ in Metabolic Dysfunction-Associated Steatotic Liver Disease.

> **英文摘要：**
> Elevated liver stiffness is closely associated with morbidity and mortality in metabolic dysfunction-associated steatotic liver disease (MASLD). However, the contribution of increased stiffness to impaired liver function is poorly understood. Here, we demonstrate that hepatic cholesterol levels are determined by the stiffness of the liver. In the human MASLD cohort and a mouse model, intrahepatic cholesterol levels strongly correlated with liver stiffness. We show that a stiff matrix promotes spontaneous accumulation of cholesterol in isolated hepatocytes. As the underlying mechanism, we found that Liver X receptor alpha (LXRα) is mechanosensitively repressed. Activation of Yes-associated protein (YAP) and Transcriptional coactivator with PDZ-binding motif (TAZ) by exposure to stiff substrate, serum stimulation, low-density culture, or deletion of Large tumor suppressor kinase 1 and 2 (LATS1/2) robustly repressed LXRα activity. In the nucleus, YAP disrupted heterodimerization of LXRα with Retinoid X receptor alpha (RXRα) independently of their transcriptional activity. Consistently, hepatocyte-specific ablation of Yap/Taz facilitated hepatic cholesterol efflux and delayed cholesterol-induced fibrosis progression in mice. Transcriptomic analysis of MASLD patient livers confirmed a strong inverse correlation between LXRα target gene expression and liver stiffness as well as YAP/TAZ activity. These findings reveal the mechanosensitive regulation of hepatic cholesterol levels in MASLD, suggesting liver stiffness as a causal factor for hepatocyte dysfunction.

> **中文摘要：**
> 在代谢功能障碍相关脂肪性肝病（MASLD）中，肝脏硬度增加与发病率和死亡率密切相关。然而，硬度增加对肝功能受损的具体贡献尚不清楚。在此，我们证明肝脏胆固醇水平是由肝脏硬度决定的。在人类 MASLD 队列和研究小鼠模型中，肝内胆固醇水平与肝脏硬度呈强相关。我们发现，高硬度基质会促进分离肝细胞中胆固醇的自发蓄积。作为其潜在机制，我们发现肝 X 受体 α (LXRα) 受到了机械敏感性的抑制。通过暴露于高硬度底物、血清刺激、低密度培养或缺失大肿瘤抑制激酶 1 和 2 (LATS1/2) 来激活 Yes 相关蛋白 (YAP) 和具有 PDZ 结合基序的转录共激活因子 (TAZ)，可显著抑制 LXRα 活性。在细胞核内，YAP 破坏了 LXRα 与类视黄醇 X 受体 α (RXRα) 的异二聚化，且这种作用独立于它们的转录活性。一致地，肝细胞特异性敲除 Yap/Taz 促进了小鼠肝脏胆固醇的外排，并延缓了胆固醇诱导的纤维化进展。对 MASLD 患者肝脏的转录组分析证实，LXRα 靶基因表达与肝脏硬度以及 YAP/TAZ 活性之间存在显著的负相关。这些发现揭示了 MASLD 中肝脏胆固醇水平的机械敏感性调节机制，表明肝脏硬度是导致肝细胞功能障碍的因果因素。

### 第二部分 AI 大师评价

本研究深入探讨了肝脏机械物理特性在代谢功能障碍相关脂肪性肝病（MASLD）发病中的核心作用，首次揭示了肝脏硬度对胆固醇代谢的直接调控逻辑。研究发现，高硬度微环境通过激活 YAP/TAZ 信号通路，在细胞核内物理性干扰 LXRα-RXRα 异二聚体的形成，从而抑制胆固醇外排并诱导脂质蓄积。该发现不仅确立了肝脏硬度作为致病因子的生物学地位，还为针对力学信号转导通路治疗慢性肝病提供了重要的分子靶点。研究通过临床样本与动物模型双向验证，具有极高的学术价值和临床转化潜力。

---

## 29. STING-NF-κB 信号通路构建了流感跨物种传播屏障

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41747053)
**期刊：** Science (New York, N.Y.)
**PMID：** 41747053
**DOI：** 10.1126/science.ads4405

### 第一部分 原文与翻译

**英文原标题：** STING-NF-κB signaling builds an influenza spillover barrier.

> **英文摘要：**
> Influenza pandemics are often traced back to the spillover of avian influenza A viruses (IAVs) to humans. However, barriers against IAV transmission remain elusive. We demonstrated human stimulator of interferon genes (STING) as a transmission barrier against IAVs. STING activated nuclear factor κB (NF-κB) and downstream NF-κB-stimulated genes (NSGs) through a specific domain. Among these NSGs, () was crucial for IAV restriction. Some IAVs have evolved to evade activating human STING by mutating residue 115 in their matrix protein 1 (M1), which is essential for efficient viral replication in human respiratory cells. This barrier against the zoonotic threat of IAVs provides a tool for future investigations into the biological functions of the cyclic guanosine monophosphate-adenosine monosphosphate (cGMP-AMP) synthase (cGAS)-STING-NF-κB signaling pathway.

> **中文摘要：**
> 流感大流行通常可追溯至禽流感 A 型病毒（IAVs）向人类的溢出。然而，针对 IAV 传播的屏障仍不清楚。我们证明了人类干扰素基因刺激因子（STING）是抗 IAVs 的一种传播屏障。STING 通过一个特定结构域激活核因子 κB (NF-κB) 及其下游的 NF-κB 刺激基因 (NSGs)。在这些 NSG 中，() 对限制 IAV 至关重要。一些 IAVs 已进化出通过其基质蛋白 1 (M1) 第 115 位残基的突变来逃避激活人类 STING 的能力，这对于病毒在人类呼吸道细胞中的高效复制至关重要。这种针对 IAVs 人畜共患威胁的屏障为未来研究环磷酸鸟苷-磷酸腺苷合成酶 (cGAS)-STING-NF-κB 信号通路的生物学功能提供了工具。

### 第二部分 AI 大师评价

这项研究揭示了 STING-NF-κB 信号通路在阻止禽流感病毒向人类跨物种溢出中的关键防御作用。作者发现 STING 通过特定结构域激活抗病毒效应基因，而流感病毒则通过 M1 蛋白的位点突变实现免疫逃逸，这解释了病毒在人类细胞中高效复制的选择压力。该研究不仅阐明了宿主限制因子的分子机制，还为理解 cGAS-STING 通路的广谱免疫功能提供了重要证据，对预警流感大流行具有重要意义。

---

## 30. 肠道微生物相互作用的失衡作为健康与疾病的标志物

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41747050)
**期刊：** Science (New York, N.Y.)
**PMID：** 41747050
**DOI：** 10.1126/science.ady1729

### 第一部分 原文与翻译

**英文原标题：** Imbalance in gut microbial interactions as a marker of health and disease.

> **英文摘要：**
> Imbalances in the human gut microbiome, or dysbioses, are associated with multiple diseases but remain poorly understood. Existing biomarkers of dysbiosis fail to capture the ecological mechanisms that differentiate healthy from diseased microbiomes. We have developed a metric, the ecological network balance index (ENBI), that quantifies the balance between positive and negative microbial interactions. This metric was inspired by the phenomenology observed in a model for gut microbiome dynamics that we introduce in this work, which revealed alternative stable states with distinct emergent microbial communities: a healthy state dominated by negative interactions and a dysbiotic state dominated by positive interactions. The ENBI robustly differentiates these states in both simulated and empirical datasets spanning multiple diseases and correlates with disease progression in conditions such as colorectal cancer, which underscores its potential as a diagnostic tool.

> **中文摘要：**
> 人类肠道微生物群的失衡（即菌群失调）与多种疾病相关，但目前对其了解仍然有限。现有的菌群失调生物标志物未能捕捉到区分健康与患病微生物组的生态学机制。我们开发了一种名为生态网络平衡指数（ENBI）的指标，用于量化正向与负向微生物相互作用之间的平衡。该指标的灵感源于我们在本研究中引入的肠道微生物组动力学模型所观察到的现象学特征，该模型揭示了具有不同涌现微生物群落的替代稳态：以负相互作用为主的健康状态和以正相互作用为主的菌群失调状态。ENBI在跨越多种疾病的模拟和实证数据集中都能稳健地区分这些状态，并与结直肠癌等疾病的进展相关，这凸显了其作为诊断工具的潜力。

### 第二部分 AI 大师评价

该研究创新性地提出了生态网络平衡指数（ENBI），通过量化微生物间正负相互作用的平衡，填补了传统生物标志物无法捕捉肠道生态演化机制的空白。研究揭示了健康肠道由负反馈（竞争）主导，而疾病状态则由正反馈（协同）驱动的底层生态逻辑。ENBI在模拟与多病种实证数据中均表现出极强的稳健性，尤其在结直肠癌等疾病的进展预测中展现了巨大的临床诊断应用潜力。

---

## 31. 灵敏的 CAR T 细胞重新定义了实体瘤中可靶向的 CD70 表达

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41747043)
**期刊：** Science (New York, N.Y.)
**PMID：** 41747043
**DOI：** 10.1126/science.adv7378

### 第一部分 原文与翻译

**英文原标题：** Sensitive CAR T cells redefine targetable CD70 expression in solid tumors.

> **英文摘要：**
> Solid tumor antigen heterogeneity is a major challenge for cancer immunotherapies, including chimeric antigen receptor (CAR) T cells. Unlike CD19 for B cell malignancies, no target with pan-cellular expression in solid tumors and absence in normal vital cells has been identified. CD70 is a promising candidate, physiologically confined to immune cell subsets and aberrantly expressed in many cancers. We show that heterogeneous CD70 expression in tumors is epigenetically regulated, ranging from high to very low in individual cells, appearing negative by conventional detection methods. Using a highly sensitive CD70 receptor, HLA-independent T cell (HIT) receptor coexpressing CD80 and 4-1BBL for costimulation, we efficiently eliminated CD70-heterogeneous tumors that evade prototypic CAR T cells. These findings provide a potential strategy to treat a broad range of solid tumors.

> **中文摘要：**
> 实体瘤抗原的异质性是癌症免疫疗法（包括嵌合抗原受体 [CAR] T 细胞）面临的主要挑战。与 B 细胞恶性肿瘤中的 CD19 不同，目前尚未发现在实体瘤中呈泛细胞表达且在正常生命关键细胞中缺失的靶点。CD70 是一个极具前景的候选靶点，其生理分布仅局限于免疫细胞亚群，但在多种癌症中异常表达。我们证明，肿瘤中异质性的 CD70 表达受到表观遗传调控，单个细胞中的表达水平从极高到极低不等，在常规检测方法下可能显示为阴性。通过使用一种高灵敏度的 CD70 受体，即共同表达 CD80 和 4-1BBL 以提供共刺激信号的 HLA 独立 T 细胞 (HIT) 受体，我们有效地清除了能够逃避常规 CAR T 细胞攻击的 CD70 异质性肿瘤。这些发现为治疗广泛的实体瘤提供了一种潜在策略。

### 第二部分 AI 大师评价

该研究针对实体瘤抗原异质性导致的免疫逃逸难题，提出了一种基于高灵敏度受体的新型 T 细胞疗法。研究揭示了 CD70 在肿瘤中存在受表观遗传调控的极低水平表达，且这种表达超出了常规检测的阈值，从而重新定义了其作为广谱靶点的潜力。通过构建共表达 CD80 和 4-1BBL 的 HIT 受体系统，该研究成功展示了对低抗原丰度肿瘤细胞的强效杀伤，为克服实体瘤治疗中“靶点不均”的痛点提供了极具创新性的解决方案。

---

## 32. 并发的L1逆转录转座事件促进人类肿瘤发生中的相互易位

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41747018)
**期刊：** Science (New York, N.Y.)
**PMID：** 41747018
**DOI：** 10.1126/science.aee4513

### 第一部分 原文与翻译

**英文原标题：** Concurrent L1 retrotransposition events promote reciprocal translocations in human tumorigenesis.

> **英文摘要：**
> LINE-1 (L1) retrotransposition generates somatic genomic variation in human cancer, but short-read sequencing has limited our understanding of its structural consequences and dynamics. Using long-read sequencing, we analyzed 10 tumors with exceptionally high retrotransposition activity, comprising over 6,000 somatic events. We reveal that L1-mediated reciprocal translocations occur frequently, typically driven by two concurrent L1 retrotransposition events on non-homologous chromosomes. Using an independent tumor cohort spanning low to high L1 activity, we estimate that retrotransposon-mediated rearrangements arise at a frequency of one event per 60 somatic retrotranspositions. Molecular timing analyses indicate that these events arise early in tumorigenesis, establishing L1 activity as an early driver of chromosomal instability. Our findings demonstrate that L1 contributes substantially to cancer genome evolution in certain tumors.

> **中文摘要：**
> LINE-1 (L1) 逆转录转座在人类癌症中产生体细胞基因组变异，但短读长测序限制了我们对其结构后果和动力学的理解。利用长读长测序，我们分析了 10 个具有极高逆转录转座活性的肿瘤，涵盖了 6,000 多个体细胞事件。我们发现 L1 介导的相互易位频繁发生，通常由非同源染色体上两个并发的 L1 逆转录转座事件驱动。通过使用一个涵盖低到高 L1 活性的独立肿瘤队列，我们估计逆转录转座子介导的重排发生频率为每 60 个体细胞逆转录转座事件中发生一次。分子计时分析表明，这些事件发生在肿瘤发生的早期，确立了 L1 活性是染色体不稳定的早期驱动因素。我们的研究结果表明，在某些肿瘤中，L1 对癌症基因组进化做出了重大贡献。

### 第二部分 AI 大师评价

本研究通过长读长测序技术，深入揭示了 LINE-1 (L1) 逆转录转座在人类癌症基因组结构变异中的关键作用。研究不仅量化了 L1 介导相互易位的发生频率，还阐明了其由非同源染色体上并发事件驱动的独特机制。分子计时分析将 L1 活性定位于肿瘤发生的早期阶段，有力地论证了其作为染色体不稳定驱动因子的地位，为理解特定癌症的基因组进化路径提供了重要证据。

---

## 33. 靶向ABCD1抑制过氧化物酶体脂肪酸氧化以选择性清除急性髓系白血病细胞

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41746867)
**期刊：** Blood
**PMID：** 41746867
**DOI：** 10.1182/blood.2025031202

### 第一部分 原文与翻译

**英文原标题：** Targeting ABCD1 inhibits peroxisomal fatty acid oxidation to selectively eliminate acute myeloid leukemia cells.

> **英文摘要：**
> Altered lipid metabolism enables growth of acute myeloid leukemia (AML) cells. While mitochondrial lipid oxidation is well characterized, the contribution of peroxisomal fatty acid oxidation (pFAO) is unclear. In this study, we demonstrate that AML cells upregulate the peroxisomal very-long-chain fatty acid (VLCFA) transporter ABCD1 and increase endogenous levels of pFAO relative to healthy hematopoietic cells. Genetic silencing or pharmacological inhibition of ABCD1, with eicosenol, impairs pFAO causing accumulation of VLCFAs and selective AML cell death in vitro and in vivo. Loss of ABCD1 disrupts peroxisomal fatty acid import and lipid homeostasis in AML, while normal progenitors remain viable by upregulating glycolysis. In murine models, ABCD1 inhibition with eicosenol reduces leukemia burden and prolongs survival without toxicity. These findings identify ABCD1 as a regulator of pFAO and a novel anti-AML therapeutic target.

> **中文摘要：**
> 脂代谢改变促进了急性髓系白血病（AML）细胞的生长。虽然线粒体脂质氧化已得到充分阐明，但过氧化物酶体脂肪酸氧化（pFAO）的贡献尚不明确。在本研究中，我们证明相对于健康造血细胞，AML细胞会上调过氧化物酶体极长链脂肪酸（VLCFA）转运蛋白ABCD1，并增加内源性pFAO水平。通过基因沉默或使用二十碳烯醇（eicosenol）对ABCD1进行药理学抑制，会损害pFAO，导致VLCFA积累，并在体内外选择性诱导AML细胞死亡。ABCD1的缺失破坏了AML细胞中的过氧化物酶体脂肪酸输入和脂质稳态，而正常祖细胞则通过上调糖酵解保持存活。在小鼠模型中，使用二十碳烯醇抑制ABCD1可减轻白血病负荷并延长生存期，且无毒性。这些发现确定了ABCD1是pFAO的调节因子，也是一种新型的抗AML治疗靶点。

### 第二部分 AI 大师评价

本研究揭示了过氧化物酶体脂肪酸氧化（pFAO）在急性髓系白血病（AML）代谢重编程中的关键作用，填补了该领域对非线粒体脂质氧化贡献认识的空白。研究精准锁定了转运蛋白ABCD1作为AML细胞的代谢软肋，并利用二十碳烯醇成功实现了选择性的抗肿瘤效果。这种基于AML细胞与正常祖细胞之间代谢代偿机制差异（糖酵解 vs pFAO）的发现，为开发兼具高疗效与低毒性的靶向药物提供了极具潜力的研发方向。

---

## 34. 患者来源的淋巴瘤球状体揭示复发/难治性B细胞非霍奇金淋巴瘤中Glofitamab耐药的预测性标志物

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41746860)
**期刊：** Blood
**PMID：** 41746860
**DOI：** 10.1182/blood.2025031309

### 第一部分 原文与翻译

**英文原标题：** Patient-Derived Lymphoma Spheroids Reveal Predictive Markers of Glofitamab Resistance in Relapsed/Refractory B-NHL.

> **英文摘要：**
> Bispecific antibodies (bsAbs) such as glofitamab represent a promising therapeutic approach for relapsed/refractory B-cell non-Hodgkin's lymphoma (R/R B-NHL), but resistance mechanisms remain poorly understood. This study aimed to identify predictive markers of bsAbs resistance based on the response of 3D patient-derived lymphoma spheroids (PDLS) established from 39 R/R B-NHL samples. PDLS were treated with glofitamab for 3 days and B-cell depletion was quantified to assess the ex-vivo treatment response. Comprehensive immune profiling was performed on patient samples using multiparametric flow cytometry, single-cell RNA sequencing, CODEX spatial proteomics and functional assays. High responders to glofitamab possessed CD8+ T-cells with consistently higher cytotoxic and activation signatures across effector differentiation states, while low responders showed enrichment of exhausted CD8+ T-cell with enhanced expression of exhaustion markers (TIGIT, LAG3, PD1). Furthermore, low responders exhibited elevated functional CD4+ T-follicular helper (Tfh) cells in close proximity to malignant B-cell thus promoting their survival through IL21 and CXCL13 signaling pathways. Analysis of pretreatment RNA-seq data from 48 R/R B-NHL patients confirmed that high Tfh abundance is associated with poor glofitamab response. In PDLS, anti-TIGIT co-treatment enhanced glofitamab efficacy in low responders, and Tfh depletion experiments confirmed that reducing Tfh activity increased B-cell depletion. Together, these findings identify CD8+ T-cell exhaustion and functionally activated Tfh cells as key factors associated with glofitamab resistance in R/R B-NHL. This work supports their potential use as predictive biomarkers for selecting patients with higher probability of response and provides a foundation for future combination therapeutic strategies.

> **中文摘要：**
> 双特异性抗体（bsAbs）如 glofitamab 是治疗复发/难治性 B 细胞非霍奇金淋巴瘤（R/R B-NHL）的一种极具前景的疗法，但其耐药机制仍不明确。本研究旨在基于从 39 个 R/R B-NHL 样本中建立的 3D 患者来源淋巴瘤球状体（PDLS）的反应，识别 bsAbs 耐药的预测性标志物。研究人员使用 glofitamab 对 PDLS 进行了为期 3 天的处理，并对 B 细胞清除情况进行了定量分析，以评估离体治疗反应。通过多参数流式细胞术、单细胞 RNA 测序、CODEX 空间蛋白质组学和功能实验，对患者样本进行了全面的免疫分析。对 glofitamab 反应良好的患者，其 CD8+ T 细胞在不同的效应分化状态下均表现出持续较高的细胞毒性和活化特征，而反应较差的患者则表现为耗竭型 CD8+ T 细胞富集，且耗竭标志物（TIGIT、LAG3、PD1）的表达增强。此外，反应较差的患者表现出功能性 CD4+ 滤泡辅助 T（Tfh）细胞增多，且这些细胞与恶性 B 细胞紧密相邻，从而通过 IL21 和 CXCL13 信号通路促进 B 细胞存活。对 48 例 R/R B-NHL 患者治疗前 RNA-seq 数据的分析证实，高 Tfh 丰度与 glofitamab 反应不佳相关。在 PDLS 模型中，抗 TIGIT 联合治疗增强了低反应者的 glofitamab 疗效，且 Tfh 清除实验证实减少 Tfh 活性可增加 B 细胞清除。总之，这些发现确定了 CD8+ T 细胞耗竭和功能活化的 Tfh 细胞是与 R/R B-NHL 中 glofitamab 耐药相关的关键因素。这项工作支持了它们作为预测性生物标志物在筛选高反应概率患者中的潜在应用，并为未来的联合治疗策略奠定了基础。

### 第二部分 AI 大师评价

该研究利用创新性的 3D 患者来源淋巴瘤球状体（PDLS）模型，结合单细胞测序和空间蛋白质组学技术，系统解析了 glofitamab 在复发/难治性 B-NHL 中的耐药异质性。研究发现 CD8+ T 细胞的耗竭表型以及 Tfh 细胞与恶性 B 细胞的空间互作是导致耐药的关键微环境因素，并提出了通过阻断 TIGIT 或抑制 Tfh 活性来克服耐药的潜在策略。这一发现不仅为临床精准筛选获益人群提供了预测性生物标志物，也为优化双抗联合治疗方案提供了重要的科学依据。

---

## 35. 我如何治疗：移植后环磷酰胺时代的造血干细胞供者选择

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41746780)
**期刊：** Blood
**PMID：** 41746780
**DOI：** 10.1182/blood.2025030823

### 第一部分 原文与翻译

**英文原标题：** How I Treat: Selection of Hematopoietic Cell Donors in the Era of Post-Transplant Cyclophosphamide.

> **英文摘要：**
> Selection of a hematopoietic progenitor cell donor for allogeneic hematopoietic cell transplantation (allo HCT) is essential for treatment planning; however, the parameters that define an "optimal" donor in the modern era are not well defined. Historically, donor-recipient human leukocyte antigen (HLA) mismatching correlated strongly with risk for graft versus host disease (GVHD) and reduced survival. For this reason, donor selection was typically hierarchical: HLA matched related and unrelated donors were evaluated first, followed by HLA mismatched donors (or deferral of HCT altogether) in patients lacking an HLA matched donor. The advent of post-transplant cyclophosphamide (PTCy)-based GVHD prevention has changed this paradigm. Survival outcomes following HLA-mismatched donor HCT with PTCy, including from related haploidentical or HLA-mismatched unrelated donors, are not different than HLA matched donor recipients in recent clinical trials and retrospective studies. These encouraging results present a new challenge: In the PTCy era, how should donors be prioritized among the many potential sources available? Herein we review HLA and non-HLA parameters that inform donor selection and discuss approaches to increase donor availability. Case vignettes focusing on concepts that may be adapted to heterogenous clinical scenarios are presented.

> **中文摘要：**
> 异基因造血细胞移植（allo HCT）中造血祖细胞供者的选择对治疗计划至关重要；然而，现代背景下定义“最佳”供者的参数尚不明确。历史上，供受者人类白细胞抗原（HLA）不匹配与移植物抗宿主病（GVHD）风险及生存率降低密切相关。为此，供者选择通常具有等级性：首先评估 HLA 匹配的亲缘和无关供者，对于缺乏 HLA 匹配供者的患者，其次考虑 HLA 不匹配供者（或完全推迟 HCT）。基于移植后环磷酰胺（PTCy）的 GVHD 预防方案的出现改变了这一范式。在最近的临床试验和回顾性研究中，采用 PTCy 的 HLA 不匹配供者 HCT（包括亲缘半相合或 HLA 不匹配无关供者）后的生存结局与 HLA 匹配供者受者无差异。这些令人鼓舞的结果提出了一个新的挑战：在 PTCy 时代，在众多潜在来源中应如何优先选择供者？在此，我们回顾了影响供者选择的 HLA 和非 HLA 参数，并讨论了增加供者可用性的方法。本文还介绍了专注于可适用于异质临床场景概念的病例摘要。

### 第二部分 AI 大师评价

本文深入探讨了异基因造血细胞移植领域中供者选择的范式转移，特别是在移植后环磷酰胺（PTCy）广泛应用的背景下。作者指出，PTCy 技术使 HLA 不匹配供者的移植疗效已能媲美传统匹配供者，从而打破了原有的层级选择模式。该综述系统总结了影响供者优劣的 HLA 与非 HLA 生物学指标，并结合临床病例为异质化临床场景下的供者优先级排序提供了科学决策框架。

---

## 36. 基于风险的乳腺癌筛查：是时候关注其实施了

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41746663)
**期刊：** JAMA oncology
**PMID：** 41746663
**DOI：** 10.1001/jamaoncol.2025.6568

### 第一部分 原文与翻译

**英文原标题：** Risk-Based Screening for Breast Cancer: Time to Focus on Implementation.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本文探讨了乳腺癌筛查模式从“一刀切”向“基于风险”的精准策略转变的关键阶段，强调了临床实施的重要性。作者指出，尽管个体化风险评估的理论依据已较为充分，但在医疗系统中落地仍面临巨大挑战。文章呼吁研究重心应从单纯的证据构建转向解决实际应用中的障碍，以确保精准医疗能真正提升筛查效率并优化资源配置。

---

## 37. 癌症患者的生育力保存

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41746655)
**期刊：** JAMA
**PMID：** 41746655
**DOI：** 10.1001/jama.2026.0070

### 第一部分 原文与翻译

**英文原标题：** Fertility Preservation in People With Cancer.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要可用。

### 第二部分 AI 大师评价

本文聚焦于癌症患者生育力保存这一关键临床领域，强调了在启动促性腺毒性治疗前进行生育力咨询与保护的重要性。文章旨在为临床医生提供关于胚胎、卵子及精子冷冻保存等前沿技术的指导，以保障肿瘤患者未来的生殖权利。作为发表在JAMA上的前沿文献，其对于优化癌症幸存者的长期生存质量具有重要的指导价值，体现了从“治愈癌症”向“全人照顾”医学模式的转变。

---

## 38. CD38+单核细胞驱动骨髓增殖性肿瘤中的纤维化

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41746641)
**期刊：** Blood
**PMID：** 41746641
**DOI：** 10.1182/blood.2025032444

### 第一部分 原文与翻译

**英文原标题：** CD38+ monocytes fuel fibrosis in myeloproliferative neoplasm.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本研究揭示了CD38+单核细胞在骨髓增殖性肿瘤（MPN）相关纤维化进程中的核心作用，阐明了特定单核细胞亚群作为纤维化驱动因子的病理机制。该发现不仅深化了对MPN骨髓微环境失调的认识，还为针对CD38分子的靶向治疗在缓解骨髓纤维化方面的应用提供了重要理论依据。尽管目前仅提供标题信息，但其研究方向对于开发新型免疫干预策略、延缓MPN疾病进展具有显著的临床转化价值。

---

## 39. 名谓何意？噬血细胞性淋巴组织细胞增多症（HLH）/高炎症综合征。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41746640)
**期刊：** Blood
**PMID：** 41746640
**DOI：** 10.1182/blood.2025032344

### 第一部分 原文与翻译

**英文原标题：** What's in a name? HLH/hyperinflammatory syndromes.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文由顶级血液学期刊《Blood》发表，深入探讨了噬血细胞性淋巴组织细胞增多症（HLH）及其相关高炎症综合征在医学命名与定义上的复杂性。文章旨在通过对术语含义的剖析，厘清此类疾病在临床表现与生物学机制上的重叠与差异。这种探讨对于标准化临床诊断标准、避免误诊以及优化高炎症状态的精准治疗路径具有重要的学术引领价值。

---

## 40. 处于十字路口：骨髓瘤中的循环肿瘤细胞

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41746637)
**期刊：** Blood
**PMID：** 41746637
**DOI：** 10.1182/blood.2025032333

### 第一部分 原文与翻译

**英文原标题：** At a crossroads: circulating tumor cells in myeloma.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本文发表于血液学顶尖期刊《Blood》，重点探讨了循环肿瘤细胞（CTC）在多发性骨髓瘤诊疗中的现状与未来趋势。标题“处于十字路口”深刻揭示了CTC作为液体活检标志物，正处于从实验室研究向临床转化应用的关键转折点。文章分析了CTC在疾病监测、预后评估及微小残留病（MRD）检测中的潜在价值，同时也指出了检测技术标准化和灵敏度提升是当前面临的主要挑战。作为一篇前瞻性论述，它为血液系统恶性肿瘤的精准医疗提供了重要的理论视角和研究方向。

---

## 41. 伴有 PDGFRA 重排的髓系/淋巴系肿瘤中 CD25+ 肥大细胞增生：一种酷似系统性肥大细胞增多症的表现

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41746636)
**期刊：** Blood
**PMID：** 41746636
**DOI：** 10.1182/blood.2025031870

### 第一部分 原文与翻译

**英文原标题：** CD25+ mast cell hyperplasia in myeloid/lymphoid neoplasm with PDGFRA rearrangement mimicking systemic mastocytosis.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本文探讨了伴有 PDGFRA 重排的髓系/淋巴系肿瘤（MLN）中一种极具误导性的临床表现，即 CD25+ 肥大细胞增生模拟了系统性肥大细胞增多症（SM）。文章核心价值在于警示临床医生，CD25 虽然是 SM 的典型标志物，但也可出现在特定基因重排的 MLN 中。研究强调了分子遗传学检测在鉴别诊断中的决定性作用，因为 PDGFRA 重排患者对伊马替尼等 TKI 治疗高度敏感，准确诊断直接关乎治疗方案的选择与预后。

---

## 42. 深度学习辅助的MRI肿瘤影像组学动态变化预测免疫联合治疗后行肝切除术的肝细胞癌患者病理学完全缓解

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41746634)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 41746634
**DOI：** 10.1097/HEP.0000000000001724

### 第一部分 原文与翻译

**英文原标题：** Deep learning-assisted tumor radiomic dynamics on MRI predict pathological complete response in HCC undergoing immune-based therapy followed by hepatectomy.

> **英文摘要：**
> BACKGROUND AIMS: Pathological complete response (pCR) following conversion therapy for initially unresectable hepatocellular carcinoma (uHCC) remains challenging to predict preoperatively. This study developed and validated a model integrating clinicopathological and radiomic features of tumor to predict pCR. METHODS: In this multi-center retrospective study, temporal radiomics features were extracted from baseline, post-treatment, and delta (change) MRIs. Serum AFP response was calculated as log₁₀(preoperative AFP)/log₁₀(baseline AFP). Univariate analysis, collinearity assessment, LASSO, and random forest were employed to perform feature selection. Fourteen machine learning models were benchmarked, with performance evaluated by using comprehensive metrics AUC, NPV, PPV, sensitivity, specificity, calibration, and decision curve analysis. RESULTS: The model was developed and validated in a training (n=78), an internal test (n=32), and an independent validation cohort (n=44). The delta radiomic model significantly outperformed both baseline (test AUC: 0.835 vs. 0.483, p<0.05; validation AUC: 0.783 vs. 0.434, p<0.05) and preoperative models (test AUC: 0.685, p<0.05; validation AUC: 0.506, p<0.05), demonstrating superior predictive performance and generalization capability in predicting lesion-level pCR. Notably, when predicting patient-level pCR, the radiomic model also showed robust discrimination, with AUCs of 0.819 in the test set and 0.781 in the validation set.The combined radiomics-AFP model achieved even higher AUCs of 0.920 (test) and 0.857 (validation) in predicting lesion-level pCR. CONCLUSION: Dynamic radiomic changes effectively predict pCR in uHCC after conversion therapy. Combining delta radiomics with AFP response significantly improves predictive performance, offering a non-invasive method for assessing pCR and potentially guiding personalized treatment decisions.

> **中文摘要：**
> 背景目的：对于初始不可切除的肝细胞癌（uHCC），转化治疗后获得病理学完全缓解（pCR）在术前预测仍具挑战性。本研究开发并验证了一个整合临床病理和肿瘤影像组学特征的模型，用于预测 pCR。方法：在这项多中心回顾性研究中，从基线、治疗后和增量（delta）变化 MRI 中提取了时空影像组学特征。血清 AFP 反应计算为 log₁₀(术前 AFP)/log₁₀(基线 AFP)。采用单变量分析、共线性评估、LASSO 和随机森林进行特征选择。对 14 种机器学习模型进行了基准测试，并使用 AUC、NPV、PPV、灵敏度、特异性、校准曲线和决策曲线分析等综合指标评估性能。结果：该模型在训练集（n=78）、内部测试集（n=32）和独立验证集（n=44）中进行了开发和验证。增量（delta）影像组学模型的表现显著优于基线模型（测试集 AUC：0.835 vs. 0.483，p<0.05；验证集 AUC：0.783 vs. 0.434，p<0.05）和术前模型（测试集 AUC：0.685，p<0.05；验证集 AUC：0.506，p<0.05），在预测病灶水平 pCR 方面展现了卓越的预测性能和泛化能力。值得注意的是，在预测患者水平 pCR 时，影像组学模型也显示出稳健的辨别力，在测试集和验证集中的 AUC 分别为 0.819 和 0.781。结合影像组学与 AFP 的模型在预测病灶水平 pCR 方面取得了更高的 AUC，分别为 0.920（测试集）和 0.857（验证集）。结论：动态影像组学变化可有效预测转化治疗后 uHCC 的 pCR。将增量影像组学与 AFP 反应相结合可显著提高预测性能，为评估 pCR 提供了非侵入性方法，并可能为指导个体化治疗决策提供参考。

### 第二部分 AI 大师评价

本研究通过多中心队列探讨了 MRI 动态影像组学在预测转化治疗后肝癌 pCR 中的价值。其核心创新点在于引入了“增量（delta）影像组学”概念，证明了动态变化特征在预测效能上显著优于单时间点静态特征。研究构建的高性能综合模型（结合 AFP 反应）在病灶和患者两个层面均通过了验证，具有较强的临床实用性。该研究为不可切除肝癌转化治疗后的非侵入性疗效评估提供了强有力的证据，对个体化手术决策具有重要指导意义。

---

## 43. 辅助伊马替尼治疗或观察在携带 KIT 外显子 9 突变的胃肠道间质瘤患者中的应用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41746633)
**期刊：** JAMA oncology
**PMID：** 41746633
**DOI：** 10.1001/jamaoncol.2026.0007

### 第一部分 原文与翻译

**英文原标题：** Adjuvant Imatinib or Observation in Patients With Gastrointestinal Stromal Tumors With KIT Exon 9 Mutations.

> **英文摘要：**
> IMPORTANCE: Gastrointestinal stromal tumors (GISTs) harboring KIT exon 9 mutations represent a biologically distinct subgroup with reduced sensitivity to standard-dose imatinib in the advanced setting. The benefit of adjuvant imatinib in this population remains uncertain. OBJECTIVE: To evaluate the association between adjuvant imatinib and recurrence-free survival (RFS) and overall survival (OS) in patients with resected GISTs with KIT exon 9 mutations. DESIGN, SETTING, AND PARTICIPANTS: This international, multicenter cohort study included patients with localized, molecularly confirmed GISTs with KIT exon 9 mutations who underwent curative-intent surgery between January 1990 and July 2022 at 35 referral centers in Europe, the US, and Japan, or were registered in the Life Raft Group database. The analysis took place between January 2025 and November 2025. EXPOSURES: Adjuvant imatinib initiated after curative surgery, modeled as a time-dependent covariate to account for immortal time bias. MAIN OUTCOMES AND MEASURES: The primary end points were RFS (time from surgery to recurrence or death) and OS (time from surgery to death) in the full cohort and in the high-risk subgroup defined by modified National Institutes of Health (mNIH) criteria. Multivariable Cox regression models included established prognostic covariates and cluster-robust standard errors. Overlap weighting (OW) based on propensity scores was used as a causal inference model. Secondary analyses evaluated 400 mg/d vs 800 mg/d dosing in the mNIH high-risk subgroup. RESULTS: A total of 367 patients were included, 187 (51.0%) male and 180 (49%) female, with a mean (SD) age of 56 (13) years. Among these, 91 (24.8%) were observed and 276 (75.2%) received adjuvant imatinib (median [IQR] duration, 27.3 [13.5-36.0] months; 116 [42.0%] treated ≥3 years). Consistent with a cytostatic activity, adjuvant imatinib in the full cohort was associated with a reduced early hazard of recurrence or death (HR, 0.19; 95% CI, 0.10-0.36), with attenuation over time (time-interaction hazard ratio [HR], 1.85 per log-year). Treatment was also associated with improved OS (HR, 0.37; 95% CI, 0.17-0.83). Similar results were obtained when limiting the analysis to patients with mNIH high-risk disease. OW models and sensitivity analyses confirmed similar associations with RFS and OS. Among 257 patients with mNIH high-risk disease receiving imatinib, no significant difference was observed between 400 mg/d and 800 mg/d dosing. CONCLUSION AND RELEVANCE: In this large international cohort study of resected GISTs with KIT exon 9 mutations, adjuvant imatinib was independently associated with delayed recurrence and improved survival. These findings support the use of adjuvant imatinib in mNIH high-risk GISTs with KIT exon 9 mutations and underscore the need for prospective studies to define optimal dosing and treatment duration.

> **中文摘要：**
> 重要性：携带 KIT 外显子 9 突变的胃肠道间质瘤 (GIST) 代表了一个生物学上独特的亚群，在晚期设置下对标准剂量伊马替尼的敏感性降低。辅助伊马替尼在该人群中的获益仍不明确。目的：评估在切除的携带 KIT 外显子 9 突变的 GIST 患者中，辅助伊马替尼与无复发生存期 (RFS) 和总生存期 (OS) 之间的关联。设计、设置和参与者：这项国际多中心队列研究纳入了在 1990 年 1 月至 2022 年 7 月期间，在欧洲、美国和日本的 35 个转诊中心接受根治性手术，或在 Life Raft Group 数据库中注册的、经分子学证实的局限性 KIT 外显子 9 突变 GIST 患者。分析于 2025 年 1 月至 11 月进行。暴露因素：根治性手术后开始的辅助伊马替尼治疗，被建模为时间依赖性协变量以解释不朽时间偏倚。主要结局和测量指标：主要终点是全队列以及由改良美国国家卫生研究院 (mNIH) 标准定义的高风险亚群的 RFS（从手术到复发或死亡的时间）和 OS（从手术到死亡的时间）。多变量 Cox 回归模型包括已确立的预后协变量和聚类稳健标准误差。基于倾向评分的重叠权重 (OW) 被用作因果推理模型。次要分析评估了 mNIH 高风险亚群中 400 mg/d 与 800 mg/d 剂量的对比。结果：共纳入 367 名患者，其中 187 名 (51.0%) 为男性，180 名 (49%) 为女性，平均 (SD) 年龄为 56 (13) 岁。其中，91 名 (24.8%) 接受观察，276 名 (75.2%) 接受辅助伊马替尼治疗（中位 [IQR] 持续时间为 27.3 [13.5-36.0] 个月；116 名 [42.0%] 治疗时间 ≥3 年）。与细胞静止活性一致，全队列中的辅助伊马替尼与复发或死亡的早期风险降低相关（HR, 0.19; 95% CI, 0.10-0.36），且风险随时间减弱（时间交互风险比 [HR]，每对数年 1.85）。治疗还与 OS 的改善相关（HR, 0.37; 95% CI, 0.17-0.83）。当分析局限于 mNIH 高风险疾病患者时，得到了类似的结果。OW 模型和敏感性分析证实了其与 RFS 和 OS 类似的关联。在接受伊马替尼治疗的 257 名 mNIH 高风险疾病患者中，400 mg/d 和 800 mg/d 剂量之间未观察到显著差异。结论和相关性：在这项针对切除的 KIT 外显子 9 突变 GIST 的大型国际队列研究中，辅助伊马替尼与延迟复发和生存改善独立相关。这些发现支持在携带 KIT 外显子 9 突变的 mNIH 高风险 GIST 中使用辅助伊马替尼，并强调需要开展前瞻性研究以确定最佳剂量和治疗持续时间。

### 第二部分 AI 大师评价

本研究通过大规模国际多中心队列分析，系统探讨了辅助伊马替尼在 KIT 外显子 9 突变 GIST 这一特殊亚群中的临床价值。研究采用了时间依赖性协变量和重叠权重等稳健的统计学方法，有效降低了回顾性研究中的偏倚，证明了辅助治疗能显著改善 RFS 和 OS。特别值得关注的是，研究发现在辅助治疗阶段 400mg 与 800mg 剂量疗效相当，这为该亚群的临床路径提供了重要参考。尽管作为回顾性研究存在一定局限性，但其样本量和严谨的因果推断为高危外显子 9 突变患者的辅助治疗方案提供了强有力的循证支持。

---

## 44. 替雷利珠单抗联合化疗一线治疗复发或转移性鼻咽癌：III期RATIONALE-309随机临床试验的三年随访结果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41746630)
**期刊：** JAMA oncology
**PMID：** 41746630
**DOI：** 10.1001/jamaoncol.2026.0020

### 第一部分 原文与翻译

**英文原标题：** First-Line Tislelizumab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer: Three-Year Follow-Up of the Phase 3 RATIONALE-309 Randomized Clinical Trial.

> **英文摘要：**
> IMPORTANCE: Nasopharyngeal carcinoma (NPC) is a major health concern in Asia, and treatment options for recurrent or metastatic disease are limited. Immunotherapy plus chemotherapy has shown promise, but long-term data are needed to guide first-line treatment. OBJECTIVE: To evaluate the 3-year efficacy and safety of tislelizumab plus chemotherapy vs placebo plus chemotherapy in participants with recurrent or metastatic NPC and explore potential biomarkers of treatment response. DESIGN, SETTING, AND PARTICIPANTS: The RATIONALE-309 trial was a double-blind, placebo-controlled phase 3 randomized clinical trial conducted in Asia from April 2019 to December 2023. Treatment-naive adults with histologically or cytologically confirmed recurrent or metastatic NPC were included. Data were analyzed from December 2023 to January 2024. INTERVENTIONS: Participants were randomized 1:1 to receive tislelizumab, 200 mg, intravenously or placebo every 3 weeks, both with gemcitabine and cisplatin for 4 to 6 cycles. Participants in the placebo arm could cross over to tislelizumab monotherapy at disease progression. MAIN OUTCOMES AND MEASURES: The primary end point was progression-free survival (PFS) assessed by an independent review committee. The primary hypothesis (PFS superiority for tislelizumab vs placebo) was specified in the protocol prior to data collection. Secondary end points included overall survival (OS), PFS after next-line therapy, and safety. RESULTS: Of 263 included participants, 206 (78.3%) were male, and the median (range) age was 50 (23-74) years; the median (range) follow-up was 27.5 (0.1-53.0) months. A total of 131 were randomized to the tislelizumab group and 132 to the placebo group. Tislelizumab plus chemotherapy demonstrated improved PFS vs placebo plus chemotherapy (median PFS, 9.6 months [95% CI, 7.6-11.6] vs 7.4 months [95% CI, 5.6-7.6]; hazard ratio [HR], 0.53; 95% CI, 0.39-0.71). The median OS was 45.3 months (95% CI, 33.4 to not estimable) vs 31.8 months (95% CI, 25.0 to not estimable), respectively (HR, 0.73; 95% CI, 0.51-1.05). Rank-preserving structural failure time analysis (HR, 0.56; 95% CI, 0.27-1.19) and 2-stage crossover-adjusted analysis (HR, 0.62; 95% CI, 0.40-0.97) showed greater OS benefit. Treatment-emergent adverse events occurred in 133 of 133 participants (100%) in the tislelizumab arm and 129 of 130 participants (99.2%) in the placebo arm, with comparable grade 3 or higher adverse event rates. Immune-mediated adverse events were more frequent with tislelizumab (71 [53.4%] vs 49 [37.7%]) but mostly of grades 1 or 2. High B-cell gene expression was associated with greater OS benefit (HR, 0.41; 95% CI, 0.23-0.74). CONCLUSIONS AND RELEVANCE: In this secondary analysis of the RATIONALE-309 randomized clinical trial, after 3 years of follow-up, tislelizumab plus chemotherapy provided sustained PFS and meaningful OS improvement vs placebo plus chemotherapy in recurrent or metastatic NPC, with an acceptable safety profile. Greater benefit was observed in participants with activated immune signatures, especially high B-cell expression. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03924986.

> **中文摘要：**
> 【重要性】鼻咽癌（NPC）是亚洲的一个主要健康问题，复发或转移性疾病的治疗选择有限。免疫疗法联合化疗已显示出前景，但仍需要长期数据来指导一线治疗。【目的】评估替雷利珠单抗联合化疗对比安慰剂联合化疗在复发或转移性鼻咽癌受试者中的3年疗效和安全性，并探索治疗反应的潜在生物标志物。【设计、场所和受试者】RATIONALE-309试验是一项于2019年4月至2023年12月在亚洲进行的双盲、安慰剂对照、III期随机临床试验。纳入了经组织学或细胞学证实的既往未经治疗的复发或转移性鼻咽癌成人患者。数据分析时间为2023年12月至2024年1月。【干预措施】受试者按1:1的比例随机分配，每3周静脉注射一次200 mg替雷利珠单抗或安慰剂，均联合吉西他滨和顺铂治疗4至6个周期。安慰剂组受试者在疾病进展时可交叉接受替雷利珠单抗单药治疗。【主要结局和指标】主要终点是由独立评审委员会评估的无进展生存期（PFS）。主要假设（替雷利珠单抗对比安慰剂的PFS优效性）在数据收集前已在方案中指定。次要终点包括总生存期（OS）、下一线治疗后的PFS以及安全性。【结果】在纳入的263名受试者中，206人（78.3%）为男性，中位年龄（范围）为50（23-74）岁；中位随访时间（范围）为27.5（0.1-53.0）个月。共131人被随机分配至替雷利珠单抗组，132人至安慰剂组。与安慰剂联合化疗相比，替雷利珠单抗联合化疗表现出改善的PFS（中位PFS，9.6个月 [95% CI, 7.6-11.6] vs 7.4个月 [95% CI, 5.6-7.6]；风险比 [HR]，0.53；95% CI, 0.39-0.71）。中位OS分别为45.3个月（95% CI, 33.4至不可估计）和31.8个月（95% CI, 25.0至不可估计）（HR, 0.73；95% CI, 0.51-1.05）。保秩结构失效率模型分析（HR, 0.56; 95% CI, 0.27-1.19）和二阶段交叉调整分析（HR, 0.62; 95% CI, 0.40-0.97）显示出更大的OS获益。替雷利珠单抗组133名受试者中的133人（100%）和安慰剂组130名受试者中的129人（99.2%）发生了治疗期间不良事件，两组3级或更高级别的不良事件发生率相当。免疫介导的不良事件在替雷利珠单抗组更常见（71 [53.4%] vs 49 [37.7%]），但大多为1级或2级。高B细胞基因表达与更大的OS获益相关（HR, 0.41; 95% CI, 0.23-0.74）。【结论和相关性】在RATIONALE-309随机临床试验的这项二次分析中，经过3年的随访，替雷利珠单抗联合化疗在复发或转移性鼻咽癌中与安慰剂联合化疗相比，提供了持续的PFS获益和具有临床意义的OS改善，且安全性特征可接受。在具有活化免疫特征的受试者中观察到了更大的获益，尤其是高B细胞表达的受试者。【临床试验注册】ClinicalTrials.gov 标识符：NCT03924986。

### 第二部分 AI 大师评价

本研究报告了RATIONALE-309试验的三年长期随访结果，证实了替雷利珠单抗联合化疗作为复发或转移性鼻咽癌（RM-NPC）一线治疗的显著优势。研究不仅展示了PFS的持续获益，还通过多种模型调整分析明确了其对OS的实质性改善，即使在存在高比例交叉治疗的情况下。此外，该研究通过生物标志物探索发现，高B细胞基因表达与更显著的生存获益相关，为精准免疫治疗提供了新的分子依据，进一步巩固了该联合方案在亚洲高发鼻咽癌人群中的标准治疗地位。

---

## 45. CHOP方案联合抗CD20疗法治疗滤泡性淋巴瘤：SWOG S0016试验的15年随访研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41746629)
**期刊：** JAMA oncology
**PMID：** 41746629
**DOI：** 10.1001/jamaoncol.2026.0042

### 第一部分 原文与翻译

**英文原标题：** Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 Trial.

> **英文摘要：**
> IMPORTANCE: Follicular lymphoma (FL) has historically been regarded as incurable, with patients experiencing late relapses after initial chemoimmunotherapy treatment. OBJECTIVE: To provide 15-year follow-up data from the SWOG S0016 trial that evaluated the potential for long-term remission and cure following chemoimmunotherapy with cyclophosphamide, hydroxydaunorubicin/doxorubicin, oncovin, and prednisone/prednisolone (CHOP)-based regimens. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, intergroup study was conducted at academic and community practice locations throughout the US and enrolled patients with untreated, advanced-stage FL. Cure modeling, which involves estimating the proportion of patients cured of the disease, was conducted by incorporating background mortality rates to estimate the proportion of patients cured of FL during the S0016 trial. Patients were enrolled between May 2001 and October 2008 and followed up for a median (IQR) of 15.5 (13.6-16.9) years. The 15-year analysis was conducted in June 2025. INTERVENTIONS: Patients were randomized to receive either rituximab plus CHOP (R-CHOP) or CHOP followed by radioimmunotherapy (CHOP-RIT). MAIN OUTCOMES: The main outcomes were 15-year progression free survival (PFS) and overall survival (OS). Secondary outcomes included cure modeling. RESULTS: A total of 531 eligible patients (242 female patients [46%]; median [IQR] age, 53 [45-61] years) were included in the final analysis (267 [50%] received R-CHOP and 264 [50%] CHOP-RIT). The overall 15-year OS was 70%, with no significant difference between treatment arms, and the 15-year PFS was 40% (95% CI, 36.0%-44.7%). CHOP-RIT demonstrated superior 15-year PFS (47% vs 34%; P = .004) compared with R-CHOP. Cure modeling estimated an overall cure rate of 42%, with the highest cure rates observed in patients with low Follicular Lymphoma International Prognostic Index scores and normal β2 microglobulin levels. The rate of relapse declined substantially over time, from 6.8% during the first 5 years to 0.6% between 15 to 20 years. CONCLUSIONS AND RELEVANCE: The results of this secondary analysis suggest that a subset of patients with advanced-stage FL can achieve cure with CHOP-based chemoimmunotherapy, as relapse rates decline over time. This finding represents a paradigm shift in the understanding of and approach to FL, with implications for initial patient discussions and future research strategies. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00006721.

> **中文摘要：**
> 重要性：历史上，滤泡性淋巴瘤（FL）一直被认为是不可治愈的，患者在初始免疫化疗后常会出现晚期复发。目的：提供SWOG S0016试验的15年随访数据，该试验评估了基于环磷酰胺、羟基柔红霉素/多柔比星、长春新碱和泼尼松/泼尼松龙（CHOP）方案的免疫化疗实现长期缓解和治愈的潜力。设计、设置和受试者：这项多中心、组间研究在美国各地的学术和社区医疗机构进行，入组了未经治疗的晚期FL患者。治愈建模通过整合背景死亡率来估算S0016试验期间FL治愈患者的比例。患者入组时间为2001年5月至2008年10月，中位（IQR）随访时间为15.5（13.6-16.9）年。15年分析于2025年6月进行。干预措施：患者被随机分配接受利妥昔单抗联合CHOP（R-CHOP）或CHOP序贯放射免疫治疗（CHOP-RIT）。主要结局指标：主要结局指标为15年无进展生存率（PFS）和总生存率（OS）。次要结局指标包括治愈建模。结果：共531名符合条件的患者（242名女性[46%]；中位[IQR]年龄53[45-61]岁）被纳入最终分析（267名[50%]接受R-CHOP，264名[50%]接受CHOP-RIT）。整体15年OS为70%，两组间无显著差异；15年PFS为40%（95% CI, 36.0%-44.7%）。与R-CHOP相比，CHOP-RIT表现出更优的15年PFS（47% vs 34%; P = .004）。治愈建模估计总体治愈率为42%，在滤泡性淋巴瘤国际预后指数（FLIPI）评分较低且β2微球蛋白水平正常的患者中治愈率最高。复发率随时间大幅下降，从前5年的6.8%降至15至20年间的0.6%。结论和相关性：该二次分析结果表明，随着复发率随时间推移而降低，一部分晚期FL患者可以通过基于CHOP的免疫化疗实现治愈。这一发现代表了对FL认识和处理方式的范式转变，对初始医患沟通和未来的研究策略具有重要意义。临床试验注册：ClinicalTrials.gov 标识符：NCT00006721。

### 第二部分 AI 大师评价

该研究通过对SWOG S0016试验长达15年的深度随访，挑战了滤泡性淋巴瘤（FL）不可治愈的传统观点。研究通过治愈建模发现，约42%的晚期FL患者在接受CHOP基础的免疫化疗后可达到临床治愈，且随访后期复发率极低。尽管CHOP-RIT在PFS上优于R-CHOP，但两者OS相当。该研究为FL的长期生存管理提供了里程碑式的证据，标志着FL从“慢性不可治愈”向“部分可治愈”疾病的认知转型。

---

## 46. 身体活动、生活方式与癌症风险——作者回复

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41746623)
**期刊：** JAMA oncology
**PMID：** 41746623
**DOI：** 10.1001/jamaoncol.2025.6511

### 第一部分 原文与翻译

**英文原标题：** Physical Activity, Lifestyle, and Cancer Risk-Reply.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本文属于学术回执（Reply），通常是原作者针对同行对其既往关于身体活动、生活方式与癌症风险研究的评论或质疑所进行的针对性答复。虽然文中未提供摘要，但此类文献在学术争鸣中至关重要，有助于澄清研究方法学细节、强化数据解释的科学性，并进一步完善身体活动在肿瘤预防领域的证据链。其核心价值在于通过互动式讨论，深度探讨生活方式干预在临床肿瘤预防中的实际应用边界。

---

## 47. 身体活动、生活方式与癌症风险。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41746622)
**期刊：** JAMA oncology
**PMID：** 41746622
**DOI：** 10.1001/jamaoncol.2025.6508

### 第一部分 原文与翻译

**英文原标题：** Physical Activity, Lifestyle, and Cancer Risk.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

该文献发表于顶级肿瘤学期刊《JAMA Oncology》，重点探讨了身体活动及生活方式干预与癌症发生风险之间的复杂关联。尽管目前暂无详细摘要，但其核心立意明确，即强调通过非药物手段进行癌症预防的重要性。这类研究通常涉及大规模流行病学数据，旨在为公众健康指南提供科学依据，对于推动肿瘤一级预防策略的制定具有重要的参考价值。

---

## 48. 在雄心与职责之间——一条并非我选择的道路

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41746621)
**期刊：** JAMA oncology
**PMID：** 41746621
**DOI：** 10.1001/jamaoncol.2025.6324

### 第一部分 原文与翻译

**英文原标题：** Between Ambition and Duty-A Path That I Did Not Choose.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本文发表于顶级肿瘤学期刊《JAMA Oncology》，根据标题判断应属于一篇叙事医学或个人感悟类文章。该文探讨了肿瘤科医师在职业晋升的雄心与作为医疗者的职责使命之间所面临的内在冲突与平衡。作者通过分享这一“非自选”的职业路径，可能旨在引发同行对医学职业生涯中意外挑战与人文关怀的深层思考，具有较强的行业共鸣与职业启示价值。

---

## 49. 筛状结构阳性与阴性的前列腺癌

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41746620)
**期刊：** JAMA oncology
**PMID：** 41746620
**DOI：** 10.1001/jamaoncol.2025.6611

### 第一部分 原文与翻译

**英文原标题：** Cribriform-Positive and -Negative Prostate Cancer.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 尚无摘要。

### 第二部分 AI 大师评价

本文探讨了筛状结构（Cribriform pattern）在前列腺癌病理评估中的核心地位。筛状结构被认为是 Gleason 4 级中极具侵袭性的亚型，其阳性状态通常预示着更高的复发风险和较差的预后。文章通过对比筛状阳性与阴性病例，强调了这一形态学特征在临床决策和风险分层中的关键作用。该研究为前列腺癌的精准病理诊断及个体化治疗方案的制定提供了重要依据。

---

## 50. 筛状结构阳性与阴性前列腺癌：作者回复

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41746607)
**期刊：** JAMA oncology
**PMID：** 41746607
**DOI：** 10.1001/jamaoncol.2025.6614

### 第一部分 原文与翻译

**英文原标题：** Cribriform-Positive and -Negative Prostate Cancer-Reply.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

该文献是发表于《JAMA Oncology》的一篇作者回复，针对筛状生长模式在前列腺癌风险评估中作用的相关学术讨论进行了回应。这类文章通常旨在进一步澄清原始研究中关于筛状病理特征对预后影响的论据或方法学细节。通过此互动，进一步明确了筛状阳性与阴性前列腺癌在临床病理诊断及患者预后分层中的关键差异和临床意义。

---

## 51. 揭示单细胞RNA测序数据中基因表达的系统发育信号

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41746302)
**期刊：** Genomics, proteomics & bioinformatics
**PMID：** 41746302
**DOI：** 10.1093/gpbjnl/qzag017

### 第一部分 原文与翻译

**英文原标题：** Unraveling the Phylogenetic Signal of Gene Expression from Single-cell RNA-seq Data.

> **英文摘要：**
> Single-cell RNA sequencing (scRNA-seq) has transformed our understanding of phenotypic heterogeneity. Although the predominant focus of scRNA-seq analyses has been assessing gene expression changes, several approaches have been proposed in recent years to identify changes at the DNA level from scRNA-seq data. In this study, we evaluated the relative performance of six strategies for calling single-nucleotide variants from scRNA-seq data using 381 single-cell transcriptomes from five cancer patients. Specifically, we focused on the quality of the inferred genotypes and the resulting single-cell phylogenies. We found that scAllele, Monopogen, and Monovar consistently returned phylogenetically informative genotype calls, providing more precise signals of discrimination between tumor and normal cells within heterogeneous samples and among distinct subclonal lineages in longitudinal samples. In addition, we evaluated the evolution of gene expression along the cell phylogenies. While most transcriptomic variation was very plastic and did not correlate with the cell phylogeny, a group of genes associated with cell cycle processes showed a strong phylogenetic signal in one of the patients, underscoring a potential link between gene expression patterns and lineage-specific traits in the context of cancer progression. In summary, our study highlights the potential of scRNA-seq data for inferring cell phylogenies to decipher the evolutionary dynamics of cell populations.

> **中文摘要：**
> 单细胞RNA测序（scRNA-seq）改变了我们对表型异质性的理解。尽管scRNA-seq分析的主要焦点一直是评估基因表达的变化，但近年来已提出了几种方法，用于从scRNA-seq数据中识别DNA水平的变化。在本研究中，我们利用来自5名癌症患者的381个单细胞转录组，评估了从scRNA-seq数据中调用单核苷酸变异（SNV）的六种策略的相对性能。具体而言，我们重点关注了推断的基因型质量以及由此产生的单细胞系统发育关系。我们发现scAllele、Monopogen和Monovar能够稳定地返回具有系统发育信息量的基因型调用，在异质样本中区分肿瘤细胞与正常细胞，以及在纵向样本中区分不同的亚克隆谱系方面提供了更精确的信号。此外，我们还评估了基因表达沿细胞系统发育的演变。虽然大多数转录组变异具有很强的可塑性，且与细胞系统发育不相关，但在其中一名患者中，一组与细胞周期过程相关的基因显示出强烈的系统发育信号，强调了在癌症进展背景下基因表达模式与谱系特异性特征之间的潜在联系。总之，我们的研究强调了利用scRNA-seq数据推断细胞系统发育以破解细胞群演化动态的潜力。

### 第二部分 AI 大师评价

本研究深入探讨了利用单细胞转录组数据推断细胞系统发育关系的可行性，系统评估了六种单核苷酸变异（SNV）检测策略的性能。研究发现scAllele、Monopogen和Monovar在处理异质性肿瘤样本时具有显著的系统发育推断优势，能精准区分亚克隆谱系。此外，研究揭示了癌症进展中基因表达与演化轨迹的关联，特别是细胞周期基因在特定谱系中的强信号。该成果为利用scRNA-seq多维度数据解析细胞群体演化动态提供了重要的方法学参考。

---

## 52. CREBBP错义突变和截短突变在生发中心发育及淋巴瘤发生中的差异作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41746257)
**期刊：** Blood
**PMID：** 41746257
**DOI：** 10.1182/blood.2025031181

### 第一部分 原文与翻译

**英文原标题：** Differential role of CREBBP missense and truncating mutations in germinal center development and lymphomagenesis.

> **英文摘要：**
> Truncating and missense mutations of the CREBBP gene are highly prevalent in follicular lymphoma (FL) and diffuse large B cell lymphoma (DLBCL), the most common lymphoid malignancies. These mutations are acquired early during tumor evolution by a common precursor cell (CPC) and lead to either complete protein loss or single amino-acid substitutions in the acetyltransferase (KAT) domain. As a result, CREBBP is impaired in its ability to acetylate enhancer histones and non-histone proteins implicated in the germinal center (GC) reaction, the structure from which these tumors originate. However, whether truncating and KAT domain missense mutations are functionally equivalent in instructing the CPC remains unexplored. Using a conditional GC-specific knock-in mouse model for the highly frequent CREBBP-R1446H amino-acid change (CrebbpRH), here we show that, compared to complete Crebbp loss, missense mutants impose distinct quantitative and qualitative effects on the GC response. CrebbpRH controls unique transcriptional programs leading to the pre-neoplastic expansion of GCs with abnormal architecture, increased percentage of Tfh cells, and a skewed immune response toward memory B-cell differentiation. Expression of CrebbpRH, but not Crebbp loss, was by itself sufficient to initiate malignant transformation, indicating a stronger tumor-promoting activity. Of note, lymphoma cells with CREBBPRH and CREBBP loss showed distinct sensitivity to CREBBP/p300 small molecule inhibitors. Together with the differential distribution of missense and truncating mutations in FL and DLBCL, these findings have implications for the pathogenesis and therapeutic targeting of these cancers.

> **中文摘要：**
> CREBBP基因的截短突变和错义突变在滤泡性淋巴瘤（FL）和弥漫性大B细胞淋巴瘤（DLBCL）中高度流行，这两种是最常见的淋巴恶性肿瘤。这些突变在肿瘤演化早期由共同前体细胞（CPC）获得，并导致蛋白质完全缺失或乙酰转移酶（KAT）结构域中的单个氨基酸替换。结果，CREBBP乙酰化增强子组蛋白和非组蛋白的能力受损，而这些蛋白涉及生发中心（GC）反应，即这些肿瘤起源的结构。然而，截短突变和KAT结构域错义突变在指导CPC方面是否功能等效仍未得到探索。利用针对高频CREBBP-R1446H氨基酸改变（CrebbpRH）的条件性GC特异性敲入小鼠模型，我们在此证明，与完全的Crebbp缺失相比，错义突变体对GC反应施加了独特的定量和定性影响。CrebbpRH控制独特的转录程序，导致具有异常结构的GC发生肿瘤前扩张，Tfh细胞比例增加，且免疫反应向记忆B细胞分化偏倚。CrebbpRH的表达（而非Crebbp的缺失）本身就足以启动恶性转化，表明其具有更强的促癌活性。值得注意的是，具有CREBBPRH和CREBBP缺失的淋巴瘤细胞对CREBBP/p300小分子抑制剂表现出截然不同的敏感性。结合FL和DLBCL中错义突变和截短突变的差异分布，这些发现对这些癌症的发病机制和治疗靶向具有重要意义。

### 第二部分 AI 大师评价

本研究深入探讨了CREBBP基因两种常见突变类型（错义突变与截短突变）在淋巴瘤发生中的功能差异。通过建立条件性敲入小鼠模型，研究揭示了CREBBP-R1446H错义突变具有比基因缺失更强的促癌能力，能独立启动恶性转化并诱导独特的转录组重塑。该研究不仅阐明了突变特异性对生发中心微环境及免疫分化的不同影响，还发现了不同突变背景对小分子抑制剂的敏感性差异，为淋巴瘤的精准治疗提供了重要实验依据。

---

## 53. 转移性去势抵抗性前列腺癌患者循环肿瘤DNA（ctDNA）纵向分子变化的特征描述

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41746190)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41746190
**DOI：** 10.1158/1078-0432.CCR-25-3071

### 第一部分 原文与翻译

**英文原标题：** Characterizing Longitudinal Molecular Changes in ctDNA in Patients with Metastatic Castration-resistant Prostate Cancer.

> **英文摘要：**
> PURPOSE: Circulating tumor DNA (ctDNA) NGS complements tissue-based testing and offers insights into prognosis, treatment selection, and tumor evolution. Despite advances in mCRPC therapies, resistance remains a challenge. This real-world study evaluates longitudinal ctDNA changes following systemic treatments. EXPERIMENTAL DESIGN: We analyzed data from GuardantINFORM, a clinical-genomic database linking ctDNA profiles with claims data. Patients with prostate cancer who received ARPi, PARPi, or taxanes and had ctDNA testing within 3 months before and after treatment discontinuation were included. We evaluated pre- and post-treatment mutational differences and survival outcomes [Overall Survival (OS), Time to treatment discontinuation (TTD), Time to new treatment (TTNT)], stratifying by treatment type and AR alterations. RESULTS: From 36,774 prostate-cancer patients, we identified 678 with paired pre/post-ARPi, 188 with paired pre/post-PARPi, and 844 with paired pre/post-taxane ctDNA samples. Post-ARPi, the most frequent AR alterations included AR amplification (pre%/post%) (10.8%/25.6%), AR L702H (1.3%/7.9%), and AR T878A (2.9%/7.1%). Following PARPi, the most common HRR gene alterations were ATM (25%/23.4%), BRCA2 (22.9%/17%), BRCA1 (4%/2.1%), and CDK12 (5.9%/5.9%). Post-taxane, frequent alterations included TP53 (47.2%→54%), AR (33.2%/49.9%), PIK3CA (9.4%/15.9%), and EGFR (9.6%/14.6%). All treatment cohorts showed a significant increase in mutation burden post-therapy (mean increase 2.0-4.2 alterations; p<0.001). Across all three treatment groups, the presence of AR alterations was consistently associated with inferior clinical outcomes. CONCLUSIONS: Our study revealed dynamic shifts in genetic mutations in patients with mCRPC following ARPI, PARPi and taxanes. Furthermore, our findings highlight associations between AR alterations and clinical outcomes, emphasizing the potential for personalized treatment strategies.

> **中文摘要：**
> 目的：循环肿瘤DNA（ctDNA）二代测序（NGS）是对基于组织的检测的补充，并为预后评估、治疗选择和肿瘤演变提供了见解。尽管转移性去势抵抗性前列腺癌（mCRPC）的治疗取得了进展，但耐药性仍是一个挑战。这项真实世界研究评估了系统治疗后的ctDNA纵向变化。实验设计：我们分析了GuardantINFORM的数据，这是一个将ctDNA谱与理赔数据联系起来的临床基因组数据库。纳入了接受雄激素受体通路抑制剂（ARPi）、聚腺苷二磷酸核糖聚合酶抑制剂（PARPi）或紫杉烷类药物治疗，并在治疗停止前后3个月内进行过ctDNA检测的前列腺癌患者。我们评估了治疗前后的突变差异和生存结局[总生存期（OS）、治疗停止时间（TTD）、至下一次治疗时间（TTNT）]，并按治疗类型和AR改变进行分层。结果：在36,774名前列腺癌患者中，我们确定了678名具有配对的ARPi治疗前后、188名具有配对的PARPi治疗前后以及844名具有配对的紫杉烷治疗前后的ctDNA样本。ARPi治疗后，最常见的AR改变包括AR扩增（治疗前%/治疗后%）（10.8%/25.6%）、AR L702H（1.3%/7.9%）和AR T878A（2.9%/7.1%）。PARPi治疗后，最常见的同源重组修复（HRR）基因改变为ATM（25%/23.4%）、BRCA2（22.9%/17%）、BRCA1（4%/2.1%）和CDK12（5.9%/5.9%）。紫杉烷治疗后，常见的改变包括TP53（47.2%→54%）、AR（33.2%/49.9%）、PIK3CA（9.4%/15.9%）和EGFR（9.6%/14.6%）。所有治疗队列在治疗后均显示出突变负荷的显著增加（平均增加2.0-4.2个改变；p<0.001）。在所有三个治疗组中，AR改变的存在始终与较差的临床结局相关。结论：我们的研究揭示了mCRPC患者在接受ARPi、PARPi和紫杉烷类治疗后基因突变的动态转变。此外，我们的发现强调了AR改变与临床结局之间的关联，凸显了个性化治疗策略的潜力。

### 第二部分 AI 大师评价

该研究利用大规模真实世界基因组数据库，系统地刻画了mCRPC患者在接受ARPi、PARPi和紫杉烷类治疗前后的ctDNA动态演变特征。研究不仅揭示了不同治疗压力下驱动耐药的特定基因突变模式（如AR、TP53等改变的富集），还证实了AR改变与不良预后的强相关性。其创新性在于配对样本量大且覆盖多种治疗线，为液体活检在临床耐药监测和治疗决策中的应用提供了重要证据。

---

## 54. 视神经损伤后 ATF4 协调刺激轴突再生与神经退行性转录程序

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41744494)
**期刊：** eLife
**PMID：** 41744494
**DOI：** 10.7554/eLife.87528

### 第一部分 原文与翻译

**英文原标题：** Coordinated stimulation of axon regenerative and neurodegenerative transcriptional programs by ATF4 following optic nerve injury.

> **英文摘要：**
> Stress signaling is important for determining the fates of neurons following axonal insults. Previously, we showed that the stress-responsive kinase PERK contributes to injury-induced neurodegeneration (Larhammar et al., 2017). Here, we show that PERK acts primarily through activating transcription factor-4 (ATF4) to stimulate not only pro-apoptotic but also pro-regenerative responses following optic nerve damage. Using conditional knockout mice, we find an extensive PERK/ATF4-dependent transcriptional response that includes canonical ATF4 target genes and modest contributions by C/EBP Homologous Protein (CHOP). Overlap with c-Jun-dependent transcription suggests interplay with a parallel stress pathway that orchestrates regenerative and apoptotic responses. Accordingly, neuronal knockout of ATF4 recapitulates the neuroprotection afforded by PERK deficiency, and PERK or ATF4 knockout impairs optic axon regeneration enabled by disrupting the tumor suppressor PTEN. These findings reveal an integral role for PERK/ATF4 in coordinating neurodegenerative and regenerative responses to CNS axon injury.

> **中文摘要：**
> 压力信号传导对于确定轴突受损后神经元的命运至关重要。此前，我们已经证明压力反应激酶 PERK 会促进损伤诱导的神经退行性病变（Larhammar 等，2017）。在本研究中，我们证明 PERK 主要通过激活转录因子 4 (ATF4) 起作用，在视神经受损后不仅刺激促凋亡反应，还刺激促再生反应。通过使用条件性敲除小鼠，我们发现了一个广泛的 PERK/ATF4 依赖性转录反应，其中包括典型的 ATF4 靶基因，以及 C/EBP 同源蛋白 (CHOP) 的适度贡献。与 c-Jun 依赖性转录的重叠表明，其与协调再生和凋亡反应的平行压力通路存在相互作用。相应地，神经元 ATF4 敲除重现了 PERK 缺失所提供的神经保护作用，而 PERK 或 ATF4 敲除则损害了通过破坏肿瘤抑制因子 PTEN 所实现的视神经轴突再生。这些发现揭示了 PERK/ATF4 在协调中枢神经系统 (CNS) 轴突损伤的神经退行性和再生反应中发挥着不可或缺的作用。

### 第二部分 AI 大师评价

本研究深入探讨了 PERK/ATF4 通路在视神经损伤后的双重生物学功能，揭示了该通路不仅介导神经元的促凋亡程序，同时也启动了促再生转录反应。通过基因敲除小鼠模型，作者证明了 ATF4 是 PERK 下游的关键效应因子，并揭示了其与 c-Jun 通路在调控神经元命运中的交互作用。该发现具有重要的临床意义，因为它指出了在利用 PERK/ATF4 抑制剂进行神经保护治疗时，必须权衡其对轴突再生潜力的负面影响，为中枢神经系统损伤后的精准修复提供了新思路。

---

## 55. 前列腺癌患者的临床试验设计与目标：前列腺癌工作组第4版（PCWG4）建议

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41744290)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41744290
**DOI：** 10.1200/JCO-25-02834

### 第一部分 原文与翻译

**英文原标题：** Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.

> **英文摘要：**
> PURPOSE: The continuous development of new imaging approaches, molecular phenotyping, genetic subtypes, prognosis assessments, and effective therapies across a range of disease states has created a need to redefine terminology and best practices for clinical trial conduct in patients with advanced prostate cancer.
> 
> METHODS: We convened an international expert committee of diverse working groups, the Prostate Cancer Working Group 4 (PCWG4), between 2016 and 2025. Our objective was to formulate updated criteria based on emerging evidence and clinical trial data in a biomarker context to provide guidance for clinical trial design, eligibility, and end point assessments for patients with advanced prostate cancer.
> 
> RESULTS: PCWG4 redefines terminology around the disease state and previous therapies in a patient-centric context and terminology focused on androgen pathway modulation. We consider imaging, with a particular focus on positron emission tomography (PET)-defined disease. New recommendations are provided for disease state terminology, defining eligibility criteria, response and delay/prevent end points, intervals for reassessments including imaging, and patient-reported outcome determination. We provide recommendations in a biomarker-based context of use for the intended indication, reflective of patient benefit for specific interventions. We emphasize the need for development of validated PET imaging and molecular and phenotypic criteria as well as trial designs to appropriately risk stratify patients, predict and assess benefit, and measure post-treatment outcomes reliably in a trial framework.
> 
> CONCLUSION: PCWG4 updates recommendations on patient and tumor characterization, therapy development, and imaging criteria and extends guidance into earlier androgen pathway modulator-naïve/sensitive disease states to reflect an evolving, heterogeneous, and diverse patient population to optimize treatment benefits for all patients.

> **中文摘要：**
> 目的：随着涵盖一系列疾病状态的新型成像方法、分子表型、遗传亚型、预后评估以及有效疗法的不断发展，有必要重新定义晚期前列腺癌患者临床试验开展的术语和最佳实践。方法：我们在2016年至2025年间召集了一个由多个工作组组成的国际专家委员会，即前列腺癌工作组第4版（PCWG4）。我们的目标是基于生物标志物背景下的新兴证据和临床试验数据，制定更新的标准，为晚期前列腺癌患者的临床试验设计、入组标准和终点评估提供指导。结果：PCWG4在以患者为中心的背景下重新定义了关于疾病状态和既往治疗的术语，以及侧重于雄激素途径调节的术语。我们考虑了成像技术，特别关注正电子发射断层扫描（PET）定义的疾病。针对疾病状态术语、入组标准定义、缓解和延迟/预防终点、包括成像在内的复查间隔以及患者报告结局的确定，提供了新的建议。我们在基于生物标志物的预期适应症使用背景下提供了建议，反映了特定干预措施对患者的获益。我们强调需要开发经过验证的PET成像、分子和表型标准以及试验设计，以便在试验框架内对患者进行适当的风险分层、预测和评估获益，并可靠地测量治疗后的结果。结论：PCWG4更新了关于患者和肿瘤特征、药物开发和成像标准的建议，并将指导范围扩展到更早期的雄激素途径调节剂初治/敏感疾病状态，以反映不断演变、具有异质性和多样性的患者群体，从而优化所有患者的治疗获益。

### 第二部分 AI 大师评价

PCWG4共识是对前列腺癌临床研究指南的一次重大升级，旨在应对分子诊断和新型影像学（特别是PET）时代的挑战。该指南不仅更新了疾病分期和治疗反应的定义，还强调了以患者为中心的结局评估及生物标志物在风险分层中的作用。其创新之处在于将指导范围延伸至早期疾病状态，通过规范化临床试验设计，为优化异质性患者群体的个体化治疗提供了重要的学术支撑。

---

## 56. 产生抗自残且抗耗竭的 CCR4/CD7 双特异性 CAR-T 细胞

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41742839)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41742839
**DOI：** 10.1002/advs.202521443

### 第一部分 原文与翻译

**英文原标题：** Generation of CCR4/CD7 Bispecific CAR-T Cells Resistant to Fratricide and Exhaustion.

> **英文摘要：**
> The use of chimeric antigen receptor (CAR) T-cell therapy for T-cell malignancies is limited by fratricide, antigen-escape, lack of functional endurance and adverse events such as multilineage cytopenia. To address these limitations, we developed a simple single-step CD7-depletion process followed by transduction with a lentiviral vector encoding a CCR4/CD7 bispecific CAR. CD7-negative (CD7N) CCR4/CD7 CAR-T cells could expand without experiencing fratricide, unlike the bulk CCR4/CD7 CAR-T cells. The CD7N CAR-T exhibited robust cytotoxicity against malignant T-cell lines with heterogeneous CD7 and CCR4 expression in vitro and in vivo. Incorporation of EGFRt in the CAR construct allowed elimination by cetuximab in case of adverse events, whereas inclusion of c-Jun in the construct reduced functional exhaustion after repeated tumor challenges in vitro. In comparison to non-transduced CD7N cells and Bulk CAR-T cells, scRNA-seq analysis of CD7N CAR-T cells revealed a unique AQP3+ CD4+ T-cell subset following exposure to tumor cells. This cell subset exhibited broad activation of the Src/Ras/ERK and Bcl-2 pathways, high levels of SOS1 and KLF2 expression, and specific ligand-receptor interactions within the tumor necrosis factor superfamily. Collectively, these results suggest that further clinical development of CCR4/CD7 bispecific CD7N CAR-T cells is warranted, including the AQP3+ subset with SOS1/KLF2 modulation.

> **中文摘要：**
> 使用嵌合抗原受体 (CAR) T 细胞疗法治疗 T 细胞恶性肿瘤受到自残（fratricide）、抗原逃逸、功能持久性不足以及多谱系细胞减少等不良事件的限制。为解决这些限制，我们开发了一种简单的单步 CD7 去除工艺，随后使用编码 CCR4/CD7 双特异性 CAR 的慢病毒载体进行转导。与本体（bulk）CCR4/CD7 CAR-T 细胞不同，CD7 阴性 (CD7N) CCR4/CD7 CAR-T 细胞在扩增过程中不会发生自残。CD7N CAR-T 在体内和体外实验中对具有异质性 CD7 和 CCR4 表达的恶性 T 细胞系表现出强大的细胞毒性。在 CAR 结构中整合 EGFRt 使得在发生不良事件时可以通过西妥昔单抗将其清除，而结构中包含 c-Jun 则减少了在体外重复肿瘤挑战后的功能耗竭。与未转导的 CD7N 细胞和本体 CAR-T 细胞相比，对 CD7N CAR-T 细胞的单细胞 RNA 测序 (scRNA-seq) 分析揭示了在接触肿瘤细胞后出现的一个独特的 AQP3+ CD4+ T 细胞亚群。该细胞亚群表现出 Src/Ras/ERK 和 Bcl-2 通路的广泛激活、高水平的 SOS1 和 KLF2 表达，以及肿瘤坏死因子超家族内特定的配体-受体相互作用。总之，这些结果表明有必要进一步开展 CCR4/CD7 双特异性 CD7N CAR-T 细胞的临床开发，包括具有 SOS1/KLF2 调节作用的 AQP3+ 亚群。

### 第二部分 AI 大师评价

该研究针对T细胞恶性肿瘤治疗中的自残和耗竭两大痛点，创新性地结合了单步CD7敲除、双特异性抗体设计以及c-Jun过表达技术。研究不仅证明了该CAR-T系统在应对抗原异质性方面的卓越效力，还通过单细胞测序揭示了关键的AQP3+ CD4+ T细胞亚群及其信号传导机制。通过引入EGFRt安全开关，该方案兼顾了抗肿瘤活性与临床安全性，为T细胞淋巴瘤的精准免疫治疗提供了重要的新策略。

---

## 57. 利用多维度模型破译 RAC1-SPTAN1 在常染色体隐性多囊肾病（ARPKD）囊肿发生中的作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41742835)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41742835
**DOI：** 10.1002/advs.202524001

### 第一部分 原文与翻译

**英文原标题：** Deciphering the Impact of RAC1-SPTAN1 in ARPKD Cystogenesis Using Multifaceted Models.

> **英文摘要：**
> Autosomal recessive polycystic kidney disease (ARPKD) leads to severe renal cysts and progressive kidney dysfunction, with no approved treatments. The absence of such cystic phenotypes in Pkhd1/ mice underscores the need for novel models that better recapitulate the human disease. We developed kidney organoid-on-chip models that mimic patients' distal-nephron cysts, identifying RAC1/c-FOS as potential therapeutic targets. However, critical questions remain regarding RAC1 activation during cyst formation, cyst origins, and underlying molecular mechanisms. Using a multifaceted approach, organoid-on-chip models, transgenic mice, and patient kidney samples, we identified reduced levels of SPTAN1, a cytoskeletal spectrin protein, as a key regulator of RAC1 activation and cystic pathology. SPTAN1-mutant kidney organoids and mice exhibited distal-nephron cysts, and elevated RAC1/c-FOS expression, consistent with ARPKD patients. Transcriptomics and live imaging revealed altered calcium signaling and increased intracellular calcium. Single-cell RNA-seq identified SLC8A1, a sodium/calcium exchanger, as a marker distinguishing distal/connecting tubules from collecting ducts in human kidneys, predominantly expressed in cystic epithelia in organoids and human ARPKD kidneys. Restoring SPTAN1 in PKHD1/ organoids via CRISPR activation alleviated cystic phenotypes, normalized intracellular calcium, and reduced RAC1/c-FOS expression. These findings position SPTAN1 as a central player in ARPKD pathogenesis and highlight epigenome editing as a potential therapeutic strategy.

> **中文摘要：**
> 常染色体隐性多囊肾病（ARPKD）会导致严重的肾囊肿和进行性肾功能障碍，目前尚无获批的治疗方法。Pkhd1-/- 小鼠缺乏此类囊肿表型，这凸显了开发能更好模拟人类疾病的新型模型的必要性。我们开发了模拟患者远端肾单位囊肿的肾类器官芯片模型，并将 RAC1/c-FOS 鉴定为潜在的治疗靶点。然而，关于囊肿形成过程中 RAC1 的激活、囊肿起源以及潜在的分子机制仍存在关键问题。通过利用类器官芯片模型、转基因小鼠和患者肾脏样本的多维度方法，我们发现细胞骨架谱蛋白 SPTAN1 水平降低是 RAC1 激活和囊肿病理的关键调节因子。SPTAN1 突变的肾类器官和小鼠表现出远端肾单位囊肿，以及 RAC1/c-FOS 表达升高，这与 ARPKD 患者的表现一致。转录组学和活细胞成像揭示了钙信号传导的改变和胞内钙离子的增加。单细胞 RNA 测序鉴定出钠/钙交换体 SLC8A1 是区分人类肾脏远端/连接小管与集合管的标志物，其主要在类器官和人类 ARPKD 肾脏的囊肿上皮中表达。通过 CRISPR 激活在 PKHD1-/- 类器官中恢复 SPTAN1 可减轻囊肿表型，使胞内钙离子恢复正常，并降低 RAC1/c-FOS 的表达。这些发现将 SPTAN1 定位为 ARPKD 发病机制的核心参与者，并强调了表观基因组编辑作为潜在治疗策略的价值。

### 第二部分 AI 大师评价

本研究通过整合肾类器官芯片、转基因小鼠及临床样本，深入探讨了 ARPKD 的发病机制。研究不仅确定了细胞骨架蛋白 SPTAN1 在调节 RAC1 活性及胞内钙稳态中的关键作用，还首次利用 SLC8A1 明确了囊肿起源于远端肾单位。最突出的创新在于通过 CRISPR 激活技术恢复 SPTAN1 表达并成功逆转囊肿表型，为 ARPKD 的精准治疗和表观基因组编辑的临床转化提供了重要证据。

---

## 58. 靶向 FAM83D 通过激活 cGAS-STING 信号通路触发肿瘤细胞衰老并重编程肿瘤相关巨噬细胞（TAMs）以对抗胶质瘤

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41742219)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41742219
**DOI：** 10.1186/s13046-026-03681-y

### 第一部分 原文与翻译

**英文原标题：** Targeting FAM83D triggers tumor cell senescence via cGAS-STING signaling activation and reprograms TAMs to combat glioma.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本研究揭示了 FAM83D 在胶质瘤进展中的关键调控作用，发现抑制该蛋白可有效激活 cGAS-STING 信号通路，进而诱导肿瘤细胞进入衰老状态。研究的创新性在于阐明了靶向 FAM83D 不仅能直接遏制肿瘤增殖，还能通过重编程肿瘤相关巨噬细胞（TAMs）优化免疫微环境。这一双重机制为胶质瘤提供了新的联合治疗方案，具有重要的学术研究价值和潜在的临床转化意义。

---

## 59. 靶向肉瘤融合蛋白（FUS）：一种治疗特发性肺纤维化的新型反义策略

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41741410)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41741410
**DOI：** 10.1038/s41392-026-02585-9

### 第一部分 原文与翻译

**英文原标题：** Targeting fused in sarcoma (FUS): a novel antisense strategy for treating idiopathic pulmonary fibrosis.

> **英文摘要：**
> Fused in sarcoma (FUS) is a highly conserved RNA-binding protein with essential roles in RNA processing and genomic stability. While extensively studied in the context of neurodegeneration, its involvement in fibrotic diseases, particularly idiopathic pulmonary fibrosis (IPF), remains largely unexplored. This study investigated the pathological role of FUS in IPF and assessed its viability as a therapeutic target. Specifically, we examine how FUS dysregulation contributes to fibrotic signaling and evaluate whether therapeutic silencing of FUS offers a rational strategy to modulate disease progression. To assess the effects of FUS overexpression and knockdown, functional assays were performed on primary lung fibroblasts derived from healthy donors and IPF patients. Precision-cut lung slices (PCLs) and 3D alveolosphere cultures from IPF patients were treated with a FUS-targeted antisense oligonucleotide (ASO;ION363). FUS-RNA interactions were mapped via CLIP-Seq, and global transcriptional changes following FUS inhibition were analyzed via RNA sequencing. FUS overexpression in healthy fibroblasts promoted proliferation, whereas FUS knockdown attenuated the hyperproliferative phenotype in IPF fibroblasts. IPF cells demonstrated aberrant cytoplasmic mislocalization of FUS. Standard-of-care treatments (pirfenidone, nintedanib) reduced FUS expression in PCLs. CLIP-Seq revealed that FUS binds to a distinct set of profibrotic RNAs in IPF. ION363 treatment downregulated fibrotic gene programs, including those linked to ECM remodeling, TGFβ signaling, and epithelial dysfunction. In contrast, ION363 promoted functional marker expression and improved morphology in patient-derived 3D alveolospheres. We conclude that FUS is a pivotal regulator of fibrotic signaling in IPF and that targeting FUS via ASO represents a promising therapeutic avenue for IPF.

> **中文摘要：**
> 肉瘤融合蛋白（FUS）是一种高度保守的RNA结合蛋白，在RNA加工和基因组稳定性中发挥着重要作用。虽然在神经退行性疾病领域得到了广泛研究，但其在纤维化疾病，特别是特发性肺纤维化（IPF）中的作用在很大程度上仍未被探索。本研究探讨了FUS在IPF中的病理作用，并评估了其作为治疗靶点的可行性。具体而言，我们研究了FUS失调如何促进纤维化信号传导，并评估了治疗性沉默FUS是否为调节疾病进展提供了一种合理的策略。为了评估FUS过表达和敲低的影响，对来自健康捐赠者和IPF患者的原代肺成纤维细胞进行了功能分析。对来自IPF患者的精准切片肺组织（PCLs）和3D肺泡球培养物使用靶向FUS的反义寡核苷酸（ASO；ION363）进行处理。通过CLIP-Seq描绘了FUS-RNA的相互作用，并通过RNA测序分析了FUS抑制后的全球转录变化。健康成纤维细胞中的FUS过表达促进了增殖，而FUS敲低则减轻了IPF成纤维细胞的高增殖表型。IPF细胞表现出FUS异常的胞浆误定位。标准治疗药物（吡非尼酮、尼达尼布）降低了PCLs中的FUS表达。CLIP-Seq揭示了FUS在IPF中结合了一组独特的促纤维化RNA。ION363处理下调了纤维化基因程序，包括与细胞外基质（ECM）重塑、TGFβ信号传导和上皮功能障碍相关的程序。相比之下，ION363促进了患者来源的3D肺泡球中功能标记物的表达并改善了形态。我们得出结论，FUS是IPF中纤维化信号传导的关键调节因子，通过ASO靶向FUS代表了IPF的一种有前途的治疗途径。

### 第二部分 AI 大师评价

本研究创新性地揭示了RNA结合蛋白FUS在特发性肺纤维化（IPF）中的关键调控作用，打破了其传统上仅限于神经退行性疾病的研究范畴。通过整合CLIP-Seq、3D肺泡球模型和精准肺切片（PCLs）等前沿技术，研究证实了FUS通过与特定促纤维化RNA结合驱动疾病进展。应用靶向ASO（ION363）成功干预了纤维化信号并改善了肺部组织形态，为IPF的精准治疗提供了极具潜力的新型药物靶点。

---

## 60. 埃米万妥单抗联合拉泽替尼治疗EGFR突变晚期非小细胞肺癌：作者回复

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41740051)
**期刊：** The New England journal of medicine
**PMID：** 41740051
**DOI：** 10.1056/NEJMc2517120

### 第一部分 原文与翻译

**英文原标题：** Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC. Reply.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本文为针对此前发表的关于埃米万妥单抗（Amivantamab）联合拉泽替尼（Lazertinib）治疗EGFR突变晚期非小细胞肺癌（NSCLC）临床研究评论的正式作者回复。作为针对同行评议或读者质疑的回应，此类文献通常涉及对原始研究设计、亚组数据或安全性观察的深入解释与澄清。虽然不提供独立摘要，但对于全面理解MARIPOSA等相关临床试验的争论焦点及数据细节具有重要的补充参考价值。

---

## 61. 养老院居民降压治疗的减药研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41740047)
**期刊：** The New England journal of medicine
**PMID：** 41740047
**DOI：** 10.1056/NEJMc2518217

### 第一部分 原文与翻译

**英文原标题：** Reduction of Antihypertensive Treatment in Nursing Home Residents.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 尚无摘要。

### 第二部分 AI 大师评价

本文聚焦于养老院虚弱老年患者的抗高血压治疗策略，探讨了“减药治疗”（Deprescribing）在这一特定高风险人群中的临床应用。研究核心在于权衡传统血压管理目标与过度治疗带来的副作用（如低血压、跌倒风险）之间的关系。虽然该文章为短篇通讯形式且暂无详细摘要，但其对高龄衰弱患者个体化医疗的关注，反映了现代老年医学从过度干预向功能保护转化的重要趋势。

---

## 62. 恢复实体瘤中 p53 变体的功能

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41740037)
**期刊：** The New England journal of medicine
**PMID：** 41740037
**DOI：** 10.1056/NEJMe2516747

### 第一部分 原文与翻译

**英文原标题：** Restoring Function to a Variant of p53 in Solid Tumors.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

该文献发表于《新英格兰医学杂志》，深入探讨了针对实体瘤中特定p53蛋白变体进行功能修复的治疗潜能。作为最重要的抑癌基因，p53在多种癌症中发生突变，长期以来被视为极具挑战性的药物靶点。本文评价了通过创新药物或生物手段使突变型p53恢复野生型功能的最新进展，为精准医疗背景下的抗肿瘤药物研发提供了关键见解。尽管该技术尚处于前沿阶段，但其为携带常见p53突变的患者开辟了极具前景的临床路径。

---

## 63. 击中目标——HER2 阳性早期乳腺癌的个体化治疗

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41740036)
**期刊：** The New England journal of medicine
**PMID：** 41740036
**DOI：** 10.1056/NEJMe2600247

### 第一部分 原文与翻译

**英文原标题：** Hitting the Mark - Individualizing Therapy for HER2-Positive Early-Stage Breast Cancer.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本文是一篇发表在《新英格兰医学杂志》上的述评，重点探讨了 HER2 阳性早期乳腺癌治疗的个体化趋势。文章旨在分析如何在确保临床疗效的同时，通过精准识别患者获益情况来实现治疗方案的优化与降级，从而减少不必要的毒性反应。该评论强调了目前乳腺癌治疗已从“一刀切”转向基于生物学特征的精准医疗，为临床医生在选择最佳治疗强度方面提供了重要的思路和指导。

---

## 64. Rezatapopt（一种p53再激活剂）治疗Y220C突变肿瘤的1期研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41740031)
**期刊：** The New England journal of medicine
**PMID：** 41740031
**DOI：** 10.1056/NEJMoa2508820

### 第一部分 原文与翻译

**英文原标题：** Phase 1 Study of Rezatapopt, a p53 Reactivator, in  Y220C-Mutated Tumors.

> **英文摘要：**
> BACKGROUND: Rezatapopt is an investigational, first-in-class, oral, selective p53 reactivator that specifically binds to Y220C-mutated p53, which stabilizes p53 in its wild-type conformation and restores its functionality. METHODS: In this phase 1, single-group, dose-escalation and dose-optimization study, we assigned heavily pretreated patients with locally advanced or metastatic solid tumors harboring a  Y220C mutation to receive rezatapopt during continuous 21-day treatment cycles. The primary objectives were to determine the maximum tolerated dose and recommended phase 2 dose. Primary end points included dose-limiting toxic effects and adverse events. Secondary end points included preliminary efficacy and pharmacokinetic features. RESULTS: A total of 77 patients received rezatapopt at one of eight escalating doses: 150 mg, 300 mg, 600 mg, 1150 mg, 1500 mg, 2000 mg, or 2500 mg once daily or 1500 mg twice daily. The maximum tolerated dose was 1500 mg twice daily. On the basis of safety, efficacy, and pharmacokinetic data, 2000 mg once daily with food was selected as the recommended phase 2 dose. During the treatment period, 76 patients (99%) had at least one adverse event and 29 (38%) had an adverse event of grade 1 or 2. The most common adverse events were nausea (in 58% of patients), vomiting (in 44%), an increased blood creatinine level (in 39%), fatigue (in 39%), and anemia (in 36%). Treatment-related adverse events occurred in 67 patients (87%) and those of grade 1 or 2 in 48 (62%); 2 patients (3%) discontinued rezatapopt because of a treatment-related adverse event. Most gastrointestinal adverse events resolved with the treatment of symptoms and were less frequent when rezatapopt was given with food. Anemia was the most common adverse event of grade 3 or higher during the treatment period, occurring in 16% of patients. The overall response (complete or partial response) was 20% among all patients and 30% among those who had a  wild-type tumor and received a dose of at least 1150 mg once daily. Confirmed responses were seen across multiple tumor types, including ovarian and breast cancers. All patients with a response had a solid tumor that harbored  Y220C and wild-type . CONCLUSIONS: In this phase 1 study involving heavily pretreated patients, the most common adverse events associated with rezatapopt were nausea and vomiting. Antitumor activity occurred across multiple tumor types, providing proof of concept for p53 reactivation. (Funded by PMV Pharmaceuticals; PYNNACLE ClinicalTrials.gov number, NCT04585750.).

> **中文摘要：**
> 背景：Rezatapopt是一种在研的、同类首创的、口服选择性p53再激活剂，可特异性结合Y220C突变的p53，从而使p53稳定在其野生型构象并恢复其功能。方法：在这项1期、单组、剂量递增和剂量优化研究中，我们将携带Y220C突变的重度预治疗局部晚期或转移性实体瘤患者分配到连续21天的治疗周期中接受rezatapopt治疗。主要目标是确定最大耐受剂量和推荐的2期剂量。主要终点包括剂量限制性毒性反应和不良事件。次要终点包括初步疗效和药代动力学特征。结果：共有77名患者接受了八个递增剂量之一的rezatapopt治疗：150 mg、300 mg、600 mg、1150 mg、1500 mg、2000 mg或2500 mg每日一次，或1500 mg每日两次。最大耐受剂量为1500 mg每日两次。根据安全性、疗效和药代动力学数据，2000 mg随餐每日一次被选为推荐的2期剂量。在治疗期间，76名患者（99%）发生了至少一次不良事件，29名（38%）发生了1级或2级不良事件。最常见的不良事件是恶心（58%）、呕吐（44%）、血肌酐水平升高（39%）、疲劳（39%）和贫血（36%）。治疗相关不良事件发生在67名患者（87%）中，其中1级或2级见于48名（62%）；2名患者（3%）因治疗相关不良事件停用rezatapopt。大多数胃肠道不良事件在对症治疗后缓解，且随餐服用rezatapopt时发生频率较低。贫血是治疗期间最常见的3级或更高水平的不良事件，发生率为16%。在所有患者中，总缓解率（完全或部分缓解）为20%，在野生型肿瘤且接受至少1150 mg每日一次剂量的患者中为30%。在包括卵巢癌和乳腺癌在内的多种肿瘤类型中观察到确认的缓解。所有获得缓解的患者均患有携带Y220C和野生型的实体瘤。结论：在这项涉及重度预治疗患者的1期研究中，与rezatapopt相关的最常见不良事件是恶心和呕吐。在多种肿瘤类型中观察到抗肿瘤活性，为p53再激活提供了概念验证。（由PMV Pharmaceuticals资助；PYNNACLE ClinicalTrials.gov编号为NCT04585750。）

### 第二部分 AI 大师评价

这项1期临床研究评估了首创口服p53再激活剂Rezatapopt在携带Y220C突变的重度经治实体瘤患者中的安全性与初步疗效。研究确定了2000 mg QD随餐服用为推荐2期剂量，并证实其毒性谱以轻中度胃肠道反应和贫血为主，整体安全可控。最关键的是，该药物在多种肿瘤类型中展现了显著的抗肿瘤活性，成功为长期被认为“不可成药”的p53靶点再激活提供了坚实的临床概念验证。

---

## 65. 基于DNA框架的分子转换器用于逻辑驱动的精准诊断

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41739939)
**期刊：** Science advances
**PMID：** 41739939
**DOI：** 10.1126/sciadv.aeb5612

### 第一部分 原文与翻译

**英文原标题：** DNA framework-based molecular transformer for logic-driven precision diagnostics.

> **英文摘要：**
> Precision diagnostics requires logical integration of diverse biomarker information, but molecular heterogeneity and inconsistent identification kinetics hinder robust logic analysis. To overcome this, we develop a universal molecular transformer using DNA tetrahedral frameworks (DTFs) as programmable scaffolds. This system converts diverse biomarkers including proteins and variable-length nucleic acids into uniform 22-nucleotide DNA sequences, normalizing information dimensionality and identification kinetics. These uniform sequences serve as inputs for three fundamentals Boolean logic gates (AND, OR, and INHIBIT), enabling programmable molecular decision-making. Integrated on a gold-chip platform, the DTF transformer and logic system achieved statistically significant discrimination (P < 0.0001) among patients with prostate cancer, patients with benign prostatic hyperplasia, and healthy individuals using only two biomarkers (prostate-specific antigen and ALU115). By unifying signal transformation for Boolean logic computation, we resolve the critical challenges in molecular heterogeneity and establish a versatile platform for next-generation precision diagnostics.

> **中文摘要：**
> 精准诊断需要对多种生物标志物信息进行逻辑整合，但分子异质性和不一致的识别动力学阻碍了稳健的逻辑分析。为了克服这一问题，我们开发了一种通用的分子转换器，利用DNA四面体框架（DTFs）作为可编程支架。该系统将包括蛋白质和变长核酸在内的多种生物标志物转换为统一的22个核苷酸长度的DNA序列，从而实现了信息维度和识别动力学的标准化。这些统一的序列作为三种基本布尔逻辑门（与门、或门和抑制门）的输入，实现了可编程的分子决策。该DTF转换器和逻辑系统集成在金芯片平台上，仅利用两种生物标志物（前列腺特异性抗原和ALU115），就在前列腺癌患者、良性前列腺增生患者和健康个体之间实现了具有统计学意义的显著区分（P < 0.0001）。通过统一布尔逻辑运算的信号转换，我们解决了分子异质性带来的关键挑战，并为下一代精准诊断建立了一个通用平台。

### 第二部分 AI 大师评价

该研究针对临床诊断中多种生物标志物因异质性难以进行统一逻辑运算的痛点，提出了一种基于DNA四面体框架（DTF）的分子转换器方案。该方案的核心创新在于将不同类型的生物分子信号标准化为统一长度的DNA序列，从而解决了识别动力学不一致的问题，实现了稳健的布尔逻辑判别。实验在临床前列腺癌诊断中展现了极高的区分度，为构建多指标集成、逻辑驱动的下一代精准医疗诊断平台提供了重要技术支撑。

---

## 66. p27Kip1 调节 γ-珠蛋白的产生

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41411145)
**期刊：** Blood
**PMID：** 41411145
**DOI：** 10.1182/blood.2025028895

### 第一部分 原文与翻译

**英文原标题：** p27Kip1 regulates γ-globin production.

> **英文摘要：**
> Sickle cell disease (SCD) and β-thalassemia are devastating genetic disorders resulting from defects in the β-globin subunit of adult hemoglobin. Both disorders are ameliorated by the induction of γ-globin, a component of fetal hemoglobin (HbF). Therefore, the development of safe, effective, and widely available inducers of HbF is needed. Here, we discovered that slow cycling erythroid cells exhibit increased γ-globin expression. To understand the molecular basis of this, we screened all cyclin-dependent kinase inhibitors (CDKIs) for their ability to induce HbF using CRISPR activation. We found that overexpression of CDKN1B, which encodes p27Kip1 (but not overexpression of other CDKIs), induces γ-globin expression at the transcriptional level. CDKN1B mutants expressing proteins unable to bind/inhibit CDKs and/or cyclins revealed that γ-globin induction by p27Kip1 depends largely on the domains involved in its cell cycle function. Pharmacological inhibition and genetic reduction of CDK4/6 also result in increased HbF. In genetic rescue experiments, we show that p27Kip1 induces HbF by inhibiting CDK4/6, through a mechanism that is likely BCL11A and ZBTB7A independent. Furthermore, palbociclib, an oral CDK4/6 inhibitor, significantly increases HbF in a murine SCD model at doses that are well tolerated. Moreover, we show that HbF induction by hydroxyurea, a drug currently in use to treat SCD, may be mediated in part by CDK4/6 inhibition. Overall, our findings establish a causal relationship between CDK4/6 activity and γ-globin production and suggest that single or dual CDK4/6 inhibitors might be therapeutically beneficial for SCD and β-thalassemia.

> **中文摘要：**
> 镰状细胞病 (SCD) 和 β-地中海贫血是由于成人血红蛋白的 β-珠蛋白亚基缺陷导致的毁灭性遗传性疾病。这两种疾病都可以通过诱导 γ-珠蛋白（胎儿血红蛋白 [HbF] 的一个组成部分）得到缓解。因此，需要开发安全、有效且广泛可用的 HbF 诱导剂。在本研究中，我们发现慢周期红系细胞表现出 γ-珠蛋白表达增加。为了理解其分子基础，我们利用 CRISPR 激活技术筛选了所有细胞周期蛋白依赖性激酶抑制剂 (CDKIs) 诱导 HbF 的能力。我们发现，过表达编码 p27Kip1 的 CDKN1B（而非其他 CDKIs 的过表达）在转录水平上诱导了 γ-珠蛋白的表达。CDKN1B 突变体（表达无法结合/抑制 CDK 和/或细胞周期蛋白的蛋白质）揭示了 p27Kip1 对 γ-珠蛋白的诱导很大程度上取决于与其细胞周期功能相关的结构域。CDK4/6 的药理学抑制和基因减少也会导致 HbF 增加。在基因挽救实验中，我们证明 p27Kip1 通过抑制 CDK4/6 来诱导 HbF，其机制可能独立于 BCL11A 和 ZBTB7A。此外，口服 CDK4/6 抑制剂帕博西尼（palbociclib）在耐受良好的剂量下，能显著增加镰状细胞病小鼠模型中的 HbF。此外，我们还证明目前用于治疗 SCD 的药物羟基脲对 HbF 的诱导作用，可能部分是由抑制 CDK4/6 介导的。总之，我们的研究结果确立了 CDK4/6 活性与 γ-珠蛋白产生之间的因果关系，并表明单一或双重 CDK4/6 抑制剂可能对治疗 SCD 和 β-地中海贫血有益。

### 第二部分 AI 大师评价

本研究通过功能基因组筛选揭示了细胞周期调控因子 p27Kip1 在诱导胎儿血红蛋白（HbF）中的核心作用，并确定了 CDK4/6 是其下游关键靶点。研究不仅阐明了 p27Kip1 介导的 HbF 诱导独立于 BCL11A 等已知经典通路，还证明了临床已使用的 CDK4/6 抑制剂帕博西尼在动物模型中的有效性。这一发现为血红蛋白病的治疗提供了全新的药理学靶点和口服药物开发思路，具有较高的临床转化潜力。

---

## 67. ZCCHC8相关端粒生物学障碍中的体细胞遗传救助

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41288530)
**期刊：** Blood
**PMID：** 41288530
**DOI：** 10.1182/blood.2025031248

### 第一部分 原文与翻译

**英文原标题：** Somatic genetic rescue in ZCCHC8-associated telomere biology disorders.

> **英文摘要：**
> We show that somatic genetic rescue is frequent in telomere biology disorders (TBDs) caused by germ line ZCCHC8 variants. Our results highlight the critical intrinsic role of ZCCHC8 in human hematopoiesis and a potential mechanism for disease modification in TBDs.

> **中文摘要：**
> 我们发现，在由生殖系 ZCCHC8 变异引起的端粒生物学障碍（TBDs）中，体细胞遗传救助现象非常频繁。我们的研究结果强调了 ZCCHC8 在人类造血过程中的关键内在作用，并揭示了端粒生物学障碍（TBDs）中潜在的疾病修饰机制。

### 第二部分 AI 大师评价

本研究聚焦于 ZCCHC8 变异导致的端粒生物学障碍，首次系统性地证实了体细胞遗传救助在这一特定患者群体中的普遍性。研究揭示了 ZCCHC8 在维持人类正常造血功能中的核心地位，并为 TBDs 的疾病演变及内源性修复机制提供了关键证据。这一发现不仅深化了对端粒疾病复杂遗传背景的理解，也为未来的临床诊断与潜在的治疗干预策略指明了新方向。

---

速递结束，祝您工作愉快！